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ABSTRACT 
Plasma phospholipid transfer protein (PLTP) plays a crucial role in high-density lipo-
protein (HDL) metabolism and reverse cholesterol transport (RCT). It mediates the 
generation of preβ-HDL particles, enhances the cholesterol efflux from peripheral 
cells to preβ-HDL, and metabolically maintains the plasma HDL levels by facilitating 
the transfer of post-lipolytic surface remnants of triglyceride-rich lipoproteins to HDL. 
In addition to the antiatherogenic properties, recent findings indicate that PLTP has 
also proatherogenic characteristics, and that these opposite characteristics of PLTP are 
dependent on the site of PLTP expression and action. In human plasma, PLTP exists 
in a high-activity (HA-PLTP) and a low-activity form (LA-PLTP), which are associ-
ated with macromolecular complexes of different size and composition.  
The aims of this thesis were to isolate the two PLTP forms from human plasma, to 
characterize the molecular complexes in which the HA- and LA-PLTP reside, and to 
study the interactions of the PLTP forms with apolipoproteins (apo) and the ability of 
apolipoproteins to regulate PLTP activity. In addition, we aimed to study the distribu-
tion of the two PLTP forms in a Finnish population sample as well as to find possible 
regulatory factors for PLTP by investigating the influence of lipid and glucose me-
tabolism on the balance between the HA- and LA-PLTP. For these purposes, an en-
zyme-linked immunosorbent assay (ELISA) capable of determining the serum total 
PLTP concentration and quantitating the two PLTP forms separately was developed. 
In this thesis, it was demonstrated that the HA-PLTP isolated from human plasma 
copurified with apoE, whereas the LA-PLTP formed a complex with apoA-I. The 
separation of these two PLTP forms was carried out by a dextran sulfate (DxSO4)-
CaCl2 precipitation of plasma samples before the mass determination. A similar 
immunoreactivity of the two PLTP forms in the ELISA could be reached after a 
partial sample denaturation by SDS. Among normolipidemic Finnish individuals, 
the mean PLTP mass was 6.6 ± 1.5 mg/l and the mean PLTP activity 6.6 ± 1.7 
μmol/ml/h. Of the serum PLTP concentration, almost 50% represented HA-PLTP. 
The results indicate that plasma HDL levels could regulate PLTP concentration, 
while PLTP activity could be regulated by plasma triglyceride-rich very low-density 
lipoprotein (VLDL) concentration. Furthermore, new evidence is presented that 
 
 PLTP could also play a role in glucose metabolism. Finally, both PLTP forms were 
found to interact with apoA-I, apoA-IV, and apoE. In addition, both apoE and apoA-
IV, but not apoA-I, were capable of activating the LA-PLTP. These findings suggest 
that the distribution of the HA- and LA-PLTP in human plasma is subject to dy-
namic regulation by apolipoproteins. 
 
Keywords: atherosclerosis, HDL metabolism, reverse cholesterol transport, apolipo-
protein, phospholipid transfer protein 
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TIIVISTELMÄ 
Plasman fosfolipidin siirtäjäproteiinilla (PLTP) on tärkeä merkitys high-density- 
lipoproteiinien (HDL) aineenvaihdunnassa ja kolesterolin takaisinkuljetus-
järjestelmässä. PLTP kykenee muodostamaan preβ-HDL partikkeleita, lisäämään 
kolesterolin ulosvirtausta soluista näille partikkeleille, sekä ylläpitämään plasman 
HDL-tasoja kuljettamalla lipolyysin yhteydessä muodostuvia triglyseridi-pitoisten 
partikkeleiden fosfolipidijäämiä HDL-partikkeleille. Ateroskleroosin kehittymiseltä 
suojaavien ominaisuuksien lisäksi tutkimukset ovat osoittaneet, että PLTP:lla on 
myös ateroskleroosia edistäviä ominaisuuksia, ja että nämä vastakkaiset ominaisuu-
det ovat riippuvaisia PLTP:n ilmentymis- ja toimintaympäristöstä elimistössä. Ihmi-
sen verenkierrossa PLTP esiintyy aktiivisessa (high-activity, HA-PLTP) ja matala-
aktiivisessa muodossa (low-activity, LA-PLTP), jotka molemmat ovat liittyneinä 
kooltaan ja koostumukseltaan toisistaan eroaviin makromolekulaarisiin rakenteisiin. 
Tämän väitöskirjatyön tavoitteena oli eristää nämä kaksi PLTP-muotoa ihmisen 
verenkierrosta, karakterisoida molekyylirakenteet, joihin HA- ja LA-PLTP ovat 
liittyneinä, sekä tutkia PLTP-muotojen vuorovaikutusta apolipoproteiinien (apo) 
kanssa ja näiden kykyä säädellä PLTP:n aktiivisuutta. Lisäksi tavoitteena oli tutkia 
PLTP-muotojen esiintymistä suomalaisessa näyteaineistossa, sekä löytää mahdolli-
sia PLTP:n säätelytekijöitä tutkimalla sekä lipidi- että glukoosiaineenvaihdunnan 
vaikutusta HA- ja LA-PLTP:n väliseen tasapainoon. Tähän tarkoitukseen kehitettiin 
entsyymi-immunokemiallinen menetelmä (ELISA) PLTP:n kokonaispitoisuuden ja 
kahden eri PLTP-muodon pitoisuuksien määrittämiseksi. 
Tässä väitöskirjatyössä osoitettiin, että ihmisen verenkierrosta eristetty HA-PLTP -
molekyylikompleksi sisältää myös apoE:tä, kun taas LA-PLTP muodostaa komplek-
sin apoA-I:n kanssa. Nämä kaksi PLTP-muotoa erotettiin toisistaan saostamalla 
plasmanäytteet dekstraanisulfaatti (DxSO4)-CaCl2:lla ennen pitoisuuksien määrittä-
mistä. PLTP:n eri muotojen havaittiin reagoivan yhteneväisesti ELISA-
menetelmässä, jos seeruminäytteet ensin osittain denaturoitiin SDS:lla. Keskimää-
räinen PLTP-pitoisuus suomalaisessa näyteaineistossa oli 6.6 ± 1.5 mg/l ja keski-
määräinen PLTP-aktiivisuus 6.6 ± 1.7 μmol/ml/h. HA-PLTP:n osuus kokonaispitoi-
suudesta oli lähes 50 %. Tämän tutkimuksen mukaan verenkierron HDL-tasot saat-
 
 tavat säädellä PLTP:n pitoisuutta, kun taas PLTP-aktiivisuus näyttäisi liittyvän ve-
renkierron triglyseridi-rikkaiden very low-density-lipoproteiinien (VLDL) pitoisuu-
teen. Lisäksi havaittiin, että PLTP saattaa vaikuttaa myös glukoosiaineenvaihdun-
taan. Lopuksi osoitettiin, että molemmat PLTP-muodot vuorovaikuttavat apoA-I:n, 
apoA-IV:n ja apoE:n kanssa, ja sekä apoE että apoA-IV, muttei apoA-I, pystyvät 
aktivoimaan LA-PLTP:n. Perustuen tämän väitöskirjatyön tuloksiin apolipoproteii-
nit säätelevät dynaamisesti HA- ja LA-PLTP:n jakaumaa ihmisen verenkierrossa.  
 
Avainsanat: ateroskleroosi, HDL:n aineenvaihdunta, käänteinen kolesterolin kulje-
tusjärjestelmä, apolipoproteiini, fosfolipidin siirtäjäproteiini  
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 1 INTRODUCTION 
Atherosclerotic cardiovascular diseases are the major causes of death in western 
societies. The prevalence of coronary artery diseases (CAD), however, increases 
rapidly also in developing countries and formerly socialist economies of Europe. 
Thus, within the next 15 years, CAD are expected to be the main cause of death 
globally (Murray & Lopez, 1997). 
Also in Finland, despite a considerable decrease in serum cholesterol levels since the 
1980’s (Puska et al., 1995), a large part of the population has an increased risk of 
cardiovascular diseases. This is mainly due to a rising incidence of diabetes, obesity, 
and metabolic syndrome. Although the serum high-density lipoprotein (HDL) cho-
lesterol levels have increased among a part of the Finnish population, about 30% of 
the population still has too high (≥6.5 mmol/l) serum total cholesterol concentration 
(Aromaa & Koskinen, 2002). 
Lipid-modifying drugs, especially the statins, which inhibit an important rate-limiting 
enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase, have successfully been used for lowering plasma low-density lipopro-
tein (LDL) cholesterol levels in several different large-scale clinical trials (Heart Pro-
tection Study Collaborative, 2002; Ong, 2002). In addition to cholesterol lowering 
effect, statins exert many other beneficial effects such as enhancing the stability of 
atherosclerotic plaques, decreasing oxidative stress, and reducing vascular inflamma-
tion (Takemoto & Liao, 2001). Statin monotherapy, however, may have its limits in 
the inhibition of the development of CAD (Waters et al., 2004). Therefore, the treat-
ment of CAD has recently been extended and targeted to other risk factors, like low 
serum HDL cholesterol level (Linsel-Nitschke & Tall, 2005).  
The protective role of HDL is well established and was reported for the first time 
already in the 1950’s (Barr et al., 1951; Nikkilä, 1953). Several epidemiological and 
clinical studies have shown the inverse relationship between serum HDL cholesterol 
and prevalence of CAD (Assmann & Schulte, 1992; Castelli et al., 1986; Jacobs et 
al., 1990; Kannel, 1983; Kannel et al., 1979). This protective effect of HDL is inde-
pendent of other risk factors and linked to a process called reverse cholesterol trans-
port (RCT), i.e., the ability of HDL to transport cholesterol from peripheral tissues 
to the liver for excretion (Fielding & Fielding, 1995). 
One important regulator of HDL metabolism is phospholipid transfer protein, PLTP, 
which exists in high- and low-activity forms in the circulation. In this study, one 
major focus has been to investigate the distribution of these two PLTP forms in a 
Finnish population sample. For this purpose methods were developed to isolate these 
15 
 two PLTP forms and determine their concentrations in human plasma. Regulation 
mechanisms of PLTP activity and mass distribution were assessed by studying the 
interactions of PLTP with different apolipoproteins (apo) and correlating PLTP 
concentrations with different lipid and carbohydrate parameters. Finally, activation 
of the low-activity form of PLTP was studied to elucidate the possible metabolic 
roles of the two PLTP forms.  
Both human and animal studies indicate that in the future, PLTP could serve as a 
target molecule in the prevention and treatment of atherosclerotic cardiovascular 
diseases. Understanding the regulatory mechanisms of PLTP activity and concentra-
tion may lead to new therapeutic strategies selectively targeted to either of the two 
PLTP forms. 
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 2 REVIEW OF THE LITERATURE 
2.1 Atherosclerosis 
Atherosclerosis is a multifactorial, systemic disease of the large and middle-sized 
arteries that begins typically in later childhood yet being asymptomatic. It is charac-
terized by the accumulation of cholesterol, calcium, cell-waste products, and other 
substances into focal areas of the innermost layer of an arterial wall, leading to a 
local inflammation (Stary et al., 1995).  
The foamy core region of a lesion consists of extracellular lipid droplets and lipid-
laden macrophages, also known as foam cells, described by the Greek word ‘athero’ 
meaning porridge. This core region is surrounded by a protective fibrous cap con-
sisting of smooth muscle cells, collagen, and calcium that increases the arterial wall 
stiffness. Immune cells like T cells, monocytes, and mast cells infiltrate the lesion 
and produce inflammatory cytokines and proteolytic enzymes further accelerating 
the inflammatory process and causing weakening of the fibrous cap (Frostegård et 
al., 1999; Kovanen et al., 1995; Lindstedt & Kovanen, 2004). A gradual lesion de-
velopment can finally lead to a slowly progressive occlusion of the vessel lumen and 
to acute vascular events like strokes, heart attacks or peripheral vascular diseases. 
The conversion of a stable disease to a life-threatening condition is usually due to a 
plaque disruption concurrent with thrombosis (Davies, 1996; Falk et al., 1995). 
2.1.1 Risk factors for atherosclerosis 
Several retrospective and prospective autopsy studies have shown the impact of both 
genetic and environmental risk factors on the development of atherosclerotic cardio-
vascular diseases. Among the genetic risk factors, including family history of CAD, 
male gender, age, hypertension, obesity, and diabetes, elevated levels of serum total 
and LDL cholesterol as well as decreased levels of HDL cholesterol are probably the 
most important ones. Personal attributes like physical inactivity, high fat diet, and 
cigarette smoking have also been shown to associate with increased risk of cardio-
vascular diseases in several epidemiologic studies as reviewed by Solberg and 
Strong (1983). In addition, infection and chronic inflammation caused both by bac-
teria and viruses play a role in the pathogenesis of atherosclerosis (Leinonen & 
Saikku, 2002). Recently, the impact of air pollution on vascular inflammation and 
atherogenesis has been shown in an animal model (Sun et al., 2005). 
17 
 2.1.2 Development and progression of the disease 
Atherosclerotic vascular diseases have been studied for decades but only in recent 
years a remarkable progress in the research has been reached with the help of mod-
ern molecular biology approaches, research in animal models, and epidemiological 
studies of the disese. The mechanisms underlying the origin and development of the 
disease have not been fully clarified but an injury to the endothelium and the reten-
tion of atherogenic lipoproteins into subendothelial space play a central role in dis-
ease progression (Ross, 1993; Williams & Tabas, 1995). During recent years, 
atherosclerosis is generally considered as an inflammatory disease (Hansson, 2005).  
Increased total serum cholesterol in patients with hypercholesterolemia leads to 
infiltration and retention of LDL particles into the arterial intima, the innermost 
layer of an artery. Proteoglycans in the subendothelium play a critical role in the 
retention of apoB-containing lipoproteins (Skalen et al., 2002; Williams & Tabas, 
1995). Aggregation, fusion, and oxidative and enzymatic modifications of LDL 
particles lead to release of inflammatory phospholipids (Leitinger, 2003) and activa-
tion of endothelial cells causing increased expression of several leukocyte adhesion 
molecules (Cybulsky & Gimbrone, 1991; Nakashima et al., 1998). Adhesion of 
platelets to the endothelium may also stimulate the expression of adhesion mole-
cules and secretion of chemokines promoting the interaction of leukocytes with the 
activated endothelial cells (Massberg et al., 2002). Monocytes, lymphocytes, and 
other blood cells attach and migrate through the endothelial cell junctions into the 
subendothelial space where monocytes eventually differentiate into macrophages 
(Smith et al., 1995). Macrophages express a broad range of scavenger receptors and 
Toll-like receptors, which are involved in pathogen recognition, phagocytosis of 
apoptotic cells, and induction of adaptive immunity (Janeway & Medzhitov, 2002; 
Peiser et al., 2002). Scavenger receptors bind, among other polyanionic ligands, 
modified LDL particles, which results in the accumulation of excess intracellular 
cholesterol and formation of foam cells, which are the early signs of the developing 
lesion. Scavenger receptors class A and CD36 are the principal mediators of modi-
fied LDL uptake (Kunjathoor et al., 2002; Suzuki et al., 1997). Toll-like receptors, 
for their part, can induce cell activation leading to the secretion of chemokines and 
inflammatory cytokines as well as the release of proteases, reactive oxygen species, 
and nitrogen radicals. Ultimately, this leads to enhanced inflammation and tissue 
damage mediated in addition to macrophages by several other immune cells 
(Hansson, 2001). 
Chronic inflammation in an arterial wall causes changes in the concentrations of 
several plasma proteins, such as C-reactive protein (CRP), serum amyloid A (SAA), 
fibrinogen, and albumin, accompanied by the plasma lipoproteins (Gabay & 
18 
 Kushner, 1999; Khovidhunkit et al., 2004). The plasma triglyceride (TG) and very 
low-density lipoprotein (VLDL) levels increase owing to elevated hepatic fatty acid 
synthesis (Hardardottir et al., 1995), accelerated adipose tissue lipolysis (Greenberg 
et al., 2001; Zhang et al., 2002), decreased VLDL clearance (Feingold et al., 1992; 
Tripp et al., 1993), and suppressed fatty acid β-oxidation and ketogenesis (Beylot et 
al., 1989; Takeyama et al., 1990). Increasing evidence suggests a direct role for 
triglyceride-rich lipoproteins in atherogenesis (Havel, 2000; Malloy & Kane, 2001). 
Unlike the triglyceride metabolism, there are marked species-specific differences in 
the cholesterol metabolism during infection and inflammation. The total serum cho-
lesterol concentration decreases in humans and other primates, whereas in rodents 
the opposite has been reported (Feingold et al., 1995; Sammalkorpi et al., 1988). 
Although the LDL cholesterol levels decrease in humans during inflammation, the 
relative portion of small dense LDL particles increases (Feingold et al., 1993). These 
particles can rapidly enter the arterial wall intima and are more susceptible to oxida-
tive modifications leading to enhanced particle uptake by macrophages and other 
immune cells, thus promoting atherogenesis (Chait et al., 1993; Hurt-Camejo et al., 
1990). Like LDL fraction, the structure and composition of HDL particles change 
during inflammation. Various acute phase reactants, such as SAA and ceruloplas-
min, can displace apoA-I, paraoxonase-1 (PON1), and other proteins in HDL chang-
ing the particle composition to a proatherogenic direction. In addition, the concen-
trations of several enzymes and proteins regulating HDL metabolism decrease dur-
ing inflammation leading to decreased HDL levels and suppressed reverse choles-
terol transport (Van Lenten et al., 2001). Even though an immune response may 
begin as a protective process it may become excessive if prolonged and the conse-
quenses can be injurious contributing to the progression of atherosclerosis.  
2.2 Lipoprotein metabolism 
Lipoproteins are water-soluble particles consisting of a hydrophobic core of triglyc-
erides and cholesteryl esters (CE), and a hydrophilic surface of a monolayer of 
phospholipids (PL), unesterified cholesterol (UC), and apolipoproteins. Lipoproteins 
are needed to transport lipids and other hydrophobic compounds from one tissue site 
to another. They are continuously modified in the circulation by numerous proteins 
and enzymes, which alter their structure and functions. In consequence, each lipo-
protein class covers a broad range of particle sizes, densities, and compositions 
(Betteridge, 1999). Lipoproteins can be classified into five main categories depend-
ing on their size, lipid and protein composition, electrophoretic mobility, and hy-
drated density as presented in Table 1 (Havel et al., 1955). Intestinal chylomicrons 
(CM) and hepatic very low-density lipoproteins (VLDL) are secreted to the circula-
19 
 tion where the hydrolysis of the triglycerides of these particles yields smaller rem-
nant particles. VLDL hydrolysis generates intermediate-density lipoproteins (IDL) 
and low density-lipoproteins (LDL), which transport triglycerides, cholesterol, and 
other substances to the peripheral tissues where they are utilized for energy produc-
tion or synthesis of various lipid-derived compounds such as hormones.  High den-
sity-lipoproteins (HDL) function in the opposite manner transporting excess choles-
terol from non-hepatic tissues to the liver for recycling or excretion in the bile. An 
additional lipoprotein class, lipoprotein(a), is a genetically determined, very hetero-
genous group of particles, which resemble in structure the LDL and are thought to 
play a role in atherogenesis (Berglund & Ramakrishnan, 2004). The major routes for 
extracellular lipid transport, mediated by the lipoproteins, are the exogenous and 
endogenous pathways, and the process called reverse cholesterol transport, which 
are discussed below in more detail (Figure 1). 
Table 1.     Properties of the main lipoprotein classes in human plasma 
    Chemical composition  
(% of dry mass) 
Core  Surface Class Diameter 
(nm) 
Density 
(g/ml) 
Electro-
phoretic 
mobility TG CE  UC PL Prota
CM 25-500 0.93 at origin 86 3  2 7 2 
VLDL 30-80 0.95-1.006 pre-β 55 12  7 18 8 
IDL 25-35 1.006-1.019 slow pre-β 23 29  9 19 19 
LDL 18-25 1.019-1.063 β 6 42  8 22 22 
HDL2 9-12 1.063-1.125 α 5 17  5 33 40 
HDL3 7-9 1.125-1.210 α 3 13  4 25 55 
Lp(a) 30b 1.055-1.085 slow pre-β 3 33  9 22 33 
 
TG, triglyceride; CE, cholesteryl ester; UC, unesterified cholesterol; PL, phospholipid; Prot, proteins; Lp(a), 
lipoprotein(a). 
aProtein does not include bound carbohydrate. 
bThe size of Lp(a) varies a lot owing to the heterogeneity in apo(a) gene and apo(a) protein. 
Adapted from Betteridge et al., 1999. 
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 2.2.1 Exogenous lipid transport  
C h y l o m i c r o n s  
Dietary lipids and fat-soluble vitamins are absorbed from the gut and released to the 
lymphatic system and to the circulation by enterocytes in the form of chylomicrons 
(CM). Chylomicrons are heterogenous, triglyceride-rich particles ranging in diame-
ter from 25 to 500 nm. The size of the CM is dependent on the absorption rate and 
amount of free fatty acids and cholesterol, which are first esterified within the en-
terocytes and then packaged into CM. The fatty acids of chylomicron triglycerides, 
but not of phospholipids, reflect the fatty acid composition of dietary lipids (Hussain 
et al., 2001; Kayden et al., 1963). Lipid absorption promotes the release of apolipo-
proteins, which are needed for the assembly and secretion of CM. ApoB-48 is a 
prerequisite for the formation of chylomicrons. It is translated and post-
transscriptionally edited from apoB messenger ribonucleic acid (mRNA) (Powell et 
al., 1987), and in humans it is only synthesized in the gut. In addition to apoB-48, 
the intestine generates significant amounts of apoA-I and apoA-II, and all of the 
apoA-IV, which is a constituent apolipoprotein of triglyceride-rich lipoproteins as 
well as high density lipoproteins (Green & Glickman, 1981). 
Once in the circulation, chylomicrons further increase their apolipoprotein content 
by transfer of apoC and apoE from HDL particles (Havel et al., 1973). Via apoC-II, 
chylomicrons bind to the capillary endothelium-bound lipoprotein lipase (LPL) that 
hydrolyses the CM triglycerides (Fielding & Fielding, 1977). This results in the 
release of fatty acids to the surrounding tissue, principally adipose tissue and skele-
tal muscle. In addition to LPL, chylomicrons are also modified by cholesteryl ester 
transfer protein (CETP) and phospholipid transfer protein (PLTP). These two pro-
teins mediate the transfer of cholesteryl esters, phospholipids, and triglycerides be-
tween different lipoproteins in the circulation (Tall, 1995). The hydrolysis and ex-
change of CM core lipids and the loss of surface phospholipids lead to the formation 
of chylomicron remnant particles, which are depleted of triglyceride and enriched 
with cholesteryl esters, apoB-48, and apoE. CM remnants are rapidly and effectively 
cleared from the circulation through binding of apoE either to the LDL receptor 
(LDLR) or the LDL receptor-related protein (LRP) expressed on the surface of 
hepatocytes (Herz et al., 1988; Hussain et al., 1991; Windler et al., 1980a; Windler 
et al., 1980b). Thus, chylomicrons serve to transfer dietary TG and fatty acids to the 
peripheral cells for storage or oxidation and dietary cholesterol to the liver for recy-
cling or catabolism.  
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2.2.2 Endogenous lipid transport 
In addition to the lipids obtained from the diet, cholesterol and triglycerides are also 
made endogenously by the liver, which is the main organ regulating the lipid flow in 
the blood as well as in the enterohepatic circulation (Dietschy et al., 1993). Con-
comitantly with lipid synthesis, human hepatocytes synthesize a broad range of apol-
ipoproteins including apoA-I, apoA-II, apoB-100, apoC-II, apoC-III, and apoE, 
which are needed for the lipoprotein assembly and secretion (Dixon & Ginsberg, 
1993; Rash et al., 1981; Zannis et al., 1981).  
V e r y  l o w  d e n s i t y  l i p o p r o t e i n s  
ApoB-100 is an important structural protein of VLDL and LDL particles. It encom-
passes 30-40% of the protein of plasma VLDL and more than 95% of the protein 
content of plasma LDL. ApoB-100 contains both hydrophobic and hydrophilic se-
quences, which interact with lipid and water interfaces, respectively (Olofsson et al., 
1987), and a LDL receptor-binding domain needed for LDL particle uptake by both 
the peripheral and the liver cells (Knott et al., 1986; Yang et al., 1986). The assem-
bly and secretion of apoB-containing lipoproteins are regulated primarily at a post-
translational level mainly by newly synthesized lipids (Dixon & Ginsberg, 1993). 
Especially, the availability of the core lipids, cholesteryl esters and triglycerides, has 
been proposed to play a critical role in the regulation of hepatic apoB secretion rate 
and the density of the secreted lipoproteins (Cianflone et al., 1990; Dixon et al., 
1991; Fuki et al., 1989; Ginsberg et al., 1987). Moreover, studies in cultured primary 
rat hepatocytes indicate that a large proportion of newly synthesized apoB is de-
graded intracellularly (Borchardt & Davis, 1987). The presence of oleate has been 
demonstrated to inhibit the intracellular degradation of apoB in HepG2 cells (Dixon 
et al., 1991), whereas fatty acids of the ω-3 series, such as eicosapentaenoic acid and 
docosahexaenoic acid (Wang et al., 1993), as well as insulin (Sparks & Sparks, 
1993), have been reported to promote the intracellular degradation of apoB. 
The synthesis and secretion of large TG-rich VLDL particles, 40-70 nm in diameter, 
occur mainly in the postabsorptive state when the concentrations of CM and their 
remnants have decreased in the plasma. The core lipids of VLDL are either newly 
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Figure 1. Lipoprotein transport and metabolism. Solid arrows represent protein transfer processes and dashed arrows actions exerted by specific proteins
and enzymes. See text for further details. 
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 synthesized or taken up from plasma in a form of CM or other lipoprotein remnants. 
Similarly to CM, the size and density of VLDL seem to be regulated mainly by the 
cellular triglyceride content (Olofsson et al., 1987). Large VLDL1 particles are se-
creted when excess TG are available while smaller VLDL2 particles, and to some 
extent also IDL and LDL, are secreted when cellular TG concentration is reduced 
but cholesterol is present for particle assembly (Chait et al., 1980; Ginsberg et al., 
1985; Kissebah et al., 1981). VLDL particles share a common delipidation pathway 
with CM regulated by numerous enzymes and cell-surface receptors. In addition to 
apoB-100, the other apolipoproteins of VLDL, including the C apolipoproteins and 
apoE, appear to have significant roles in VLDL catabolism. ApoC-III has been pro-
posed to interfere with the interaction of apoE with the liver receptors inhibiting 
VLDL particle uptake (Windler & Havel, 1985), whereas apoC-II is an obligatory 
cofactor for LPL-mediated TG hydrolysis. As lipolysis proceeds, VLDL particles 
become smaller and denser resulting in the formation of VLDL remnants known as 
IDL. It appears that smaller VLDL2 particles are more effectively converted to IDL 
and LDL than large VLDL1 particles (Packard et al., 1984). 
I n t e r m e d i a t e  d e n s i t y  l i p o p r o t e i n s  
Hydrolysis of VLDL triglycerides by LPL generates particles that lie between 
VLDL and LDL with respect to size and density. Loss of the core lipids alters the 
surface structure of VLDL leading to reduced affinity of the C apolipoproteins to the 
surface lipids and the transfer of apoC to HDL and newly secreted VLDL and chy-
lomicrons. In consequence, intermediate density lipoproteins contain only apoB-100 
and apoE on their surface. The excess surface phospholipids are transferred to HDL 
by PLTP while CETP increases the cholesteryl ester content of VLDL and IDL 
(Eisenberg, 1985; Tall, 1995; Tall & Small, 1978). IDL are cleared from the circula-
tion by cell membrane receptors mediated by apoE or converted to LDL through the 
actions of LPL and hepatic lipase (HL) (Demant et al., 1991; Demant et al., 1988; 
Mahley, 1988; Nicoll & Lewis, 1980). 
L o w  d e n s i t y  l i p o p r o t e i n s  
The lipolytic cascade continues with the hydrolysis of the core triglycerides of IDL 
by HL inducing the transfer of apoE to HDL (Nicoll & Lewis, 1980). This results in 
the formation of LDL particles which have apoB-100 as their sole apolipoprotein. 
LDL is the principal lipoprotein fraction transporting cholesterol to the peripheral 
cells. Both the peripheral and the liver cells express LDL receptors on their surface 
but the catabolism of LDL particles is principally mediated by hepatic LDLR 
(Carew et al., 1982). Unlike macrophage scavenger receptors, the expression of 
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 LDL receptors is regulated by the intracellular cholesterol content (Brown & Gold-
stein, 1986; Kunjathoor et al., 2002; Steinberg et al., 1989). 
2.2.3 Reverse cholesterol transport 
Cells require only minor amounts of cholesterol to their essential needs like mem-
brane synthesis or hormone production. Most of them control the cholesterol ho-
meostasis by regulating the expression of plasma membrane receptors and trans-
porter proteins although cholesterol efflux by passive diffusion occurs to some ex-
tent in all cells (Phillips et al., 1987). Cholesterol efflux from peripheral macro-
phages is the first step in reverse cholesterol transport (RCT) that is defined as a 
process in which excess cholesterol of peripheral tissues is transported to the liver 
for recycling or for excretion into the bile (Glomset, 1968). Several proteins can 
mediate phospholipid and cholesterol efflux to various extracellular acceptors, espe-
cially to plasma HDL or its apolipoproteins, which play crucial roles in this process 
as illustrated in Figure 2 (von Eckardstein et al., 2001).  
H i g h  d e n s i t y  l i p o p r o t e i n s  
HDL particles are produced in both the liver and the intestine. Besides the de novo 
synthesis, nascent HDL particles are also formed during lipolysis as lipid-poor 
apoA-I becomes associated with the excess surface components of triglyceride-rich 
lipoproteins (Patsch et al., 1978; Tall et al., 1982). High-density lipoproteins are the 
smallest, densest, and the most protein-rich particles among the serum lipoproteins. 
They carry numerous proteins embedded in a phospholipid monolayer. ApoA-I and 
apoA-II are the most abundant apolipoproteins of HDL but they also contain a wide 
range of other apolipoproteins like apoE, apoA-IV, apoC, apoD, and apoJ 
(Eisenberg, 1984). Besides apolipoproteins, small amounts of various plasma en-
zymes and other proteins as well as smaller molecules are transported by HDL. 
These include lecithin:cholesterol acyl transferase (LCAT), platelet-activating factor 
acetyl hydrolase (PAF-AH), serum paraoxonase-1 (PON1), serum amyloid A 
(SAA), lipopolysaccharide (LPS), and vitamins such as beta-carotene (Van Lenten 
et al., 2001).  
In the circulation HDL undergo multiple modifications by several plasma enzymes 
and lipid transfer proteins yielding a very heterogenous group of particles. The two 
major HDL subclasses are HDL2 and HDL3, which have a globular shape and α-
mobility (von Eckardstein et al., 1994). The antiatherogenic property of HDL has 
been connected to increased concentration of HDL2 subpopulation (Ballantyne et al., 
1982; Miller et al., 1981). The smallest HDL particles, preβ-HDL, are discoidal in 
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 shape and have an important function as acceptors of excess cholesterol from pe-
ripheral tissue cells (Castro & Fielding, 1988). The unesterified cholesterol of preβ-
HDL is esterified by LCAT and transferred to the core of the particle generating 
spherical HDL3 particles. These particles can take up more unesterified cholesterol 
from the surrounding cells giving rise to larger HDL2 particles. In addition to pas-
sive diffusion (Phillips et al., 1998), specific transporter proteins like ATP-binding 
cassette transporters (ABC) of the sub-family A (Brewer et al., 2004; Wang et al., 
2003b) and the sub-family G (Klucken et al., 2000; Wang et al., 2004) as well as 
scavenger receptor class B type I (SR-BI) (Trigatti et al., 2003) have been shown to 
mediate the cholesterol efflux from cell membranes to HDL. The actions of CETP, 
HL, and PLTP have a great impact on the size, composition, and level of HDL in the 
circulation (Huuskonen et al., 2001; Wang & Briggs, 2004). CETP transports cho-
lesteryl esters from the core of HDL to less dense lipoproteins, CM, VLDL, IDL, 
and LDL, in exchange for triglycerides. Subsequently, HDL particles become en-
riched in TG and larger in size. Larger HDL2 particles are then converted into 
smaller HDL3 particles on HL-mediated hydrolysis of phospholipids and triglyc-
erides. PLTP, in turn, transfers phospholipid-rich surface remnants released during 
VLDL and CM hydrolysis to HDL. CETP, HL, and PLTP are all capable of generat-
ing preβ-HDL, thus sustaining the RCT process (Barrans et al., 1994; Lie et al., 
2001). Furthermore, PLTP has been reported to be able to modulate the activities of 
LCAT and CETP (Tollefson et al., 1988; Tu et al., 1993). The final step in RCT is 
the selective uptake of HDL-associated cholesteryl esters mediated not only by SR-
BI but also by other cell surface proteins such as HL (Brundert et al., 2003). In addi-
tion, the β-chain of ATP synthase has been shown to mediate hepatic endocytosis of 
holo-HDL particles, i.e., both apolipoproteins and lipids (Martinez et al., 2003). 
Lipid-poor apoA-I and holo-HDL particles have been found to be cleared from the 
circulation by cubilin, an endocytic receptor that is co-expressed with megalin in the 
kidney (Hammad et al., 2000; Hammad et al., 1999; Kozyraki et al., 1999). 
In addition to the important role of HDL particles in RCT, they also have other poten-
tially antiatherogenic functions (Nofer et al., 2002; Van Lenten et al., 2001). High-
density lipoproteins are able to prevent monocyte binding to the endothelium and 
penetration into the arterial intima by inhibiting the expression of several adhesion 
molecules (Cockerill et al., 1995; Navab et al., 1991). HDL, and in particular apoA-I, 
are capable of preventing the accumulation of oxidized lipids into the arterial intima, 
thus protecting LDL particles from oxidation and reducing the endocytosis of LDL by 
macrophages (Hayek et al., 1995; Navab et al., 2000). Most of these protective activi-
ties are exerted by the enzymes associated with HDL such as LCAT (Liu & Subbaiah, 
1994), PON1 (Watson et al., 1995a), and PAF-AH (Watson et al., 1995b).  
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Figure 2. Schematic model of the major pathways involved in RCT. ApoA-I, secreted by 
the liver and the intestine, released from lipolysed triglyceride-rich lipoproteins (TGRL) 
or generated by interconversion of HDL3 and HDL2, is loaded with phospholipids (PL) 
and cholesterol (C) by ABCA1. Besides apoA-I, the thus formed preβ-HDL particles 
serve as acceptors of PL and C from macrophages and other peripheral tissue cells. Inter-
action of PLTP with ABCA1 enhances the flux of excess C to preβ-HDL particles, which 
are converted to spherical HDL3 and HDL2 particles through the action of LCAT. Spheri-
cal HDL particles can be further loaded with PL and C by ABCG1 and SR-BI in macro-
phages. CETP and HL convert larger HDL2 particles into smaller HDL3 particles with a 
concomitant generation of preβ-HDL. Contrary to CETP and HL, PLTP generates preβ-
HDL from HDL3. The endocytic receptors, cubilin and megalin, act in conjunction to 
mediate the endocytosis of lipid-poor apoA-I by the kidney. Cholesteryl esters of HDL 
are transported to TGRL by CETP in exchange for triglycerides or selectively taken up 
by hepatic SR-BI. TGRL are taken up by the hepatic LDL receptor (LDLR) or the LDL 
receptor-related protein (LRP). Subsequently, C can be secreted into the bile either in the 
free form or after conversion as bile salt (BS). After transport via the bile into the intes-
tine, C and BS are reabsorbed or excreted in the feces. Solid arrows represent protein 
transfer processes and dashed arrows actions exerted by specific proteins and enzymes. 
Adapted from van der Velde & Groen, 2005. 
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 A B C  t r a n s p o r t e r s  
ABCA1 is a member of the ABC transporter superfamily of membrane bound pro-
teins that use ATP to mediate the transfer of several molecules across the cell mem-
branes. Currently, 48 ABC transporters are known to exist in humans. They can be 
divided into seven sub-families (A-G) of which the A, B, C, D, and G sub-families 
are suggested to be involved in lipid trafficking (Tannert et al., 2003). ABCA1 is a 
full-transporter that comprises of two similar halves, each containing six transmem-
brane domains and an intracellular domain with an ATP-binding cassette. ABCA1 
plays an important role in the removal of phospholipids and cholesterol from periph-
eral cells to lipid-poor apoA-I or other helical apolipoproteins of HDL (Hara & Yo-
koyama, 1991; Oram et al., 2000). Mutations in the ABCA1 gene cause Tangier 
disease and hypoalphalipoproteinemia indicating the important role of ABCA1 in 
nascent HDL particle assembly (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; 
Rust et al., 1999). In a recent study, the lipidation of newly synthesized apoA-I in 
Golgi compartments and at the plasma membrane was shown to be dependent on 
ABCA1 (Maric et al., 2005). 
ABCA1 is expressed in several human tissues and cell types. The hepatic and intes-
tinal ABCA1 contribute to the production of plasma HDL while macrophage 
ABCA1 protects arteries from lipid deposition and development of atherosclerotic 
plaques (Brunham et al., 2006; Oram et al., 2000; Timmins et al., 2005). The 
ABCA1 mRNA expression has been shown to increase during human adipocyte and 
monocyte differentiation, being strongest in lipid-loaded macrophages (Kielar et al., 
2001; Langmann et al., 1999). Interaction of ABCA1 with apoA-I or other helical 
apolipoproteins has been shown to protect it from the degradation mediated by cal-
pain protease, thereby increasing the cellular ABCA1 concentration (Arakawa & 
Yokoyama, 2002; Wang et al., 2003a). Besides the helical apolipoproteins, phos-
pholipid transfer protein (PLTP) has been shown to interact with ABCA1 and pro-
tect it from proteolysis (Oram et al., 2003). 
Similarly to ABCA1, phospholipid efflux and HDL assembly is also mediated by 
ABCA7 (Wang et al., 2003b), whereas ABCB4 and ABCB11 have been shown to 
transport mainly phosphatidylcholine and bile salts, respectively, from the liver into 
the bile (Gerloff et al., 1998; van Helvoort et al., 1996). In addition, some members 
of a sub-family of half-size ABC transporters including ABCG1, ABCG5, and 
ABCG8, have been shown to have critical roles in cholesterol transport (Figure 2). 
ABCG1 participates in the RCT process by mediating cholesterol and phospholipid 
efflux from macrophages to α-HDL (Klucken et al., 2000). It appears that the activ-
ity of ABCG1 is distinct from the activity of ABCA1 which performs the initial 
lipidation of apoA-I. The nascent preβ-HDL particles generated by ABCA1 serve as 
acceptors for ABCG1-mediated cellular cholesterol efflux (Gelissen et al., 2006). 
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 Like ABCG1, ABCG4 has been shown to mediate cholesterol efflux from macro-
phages to α-migrating HDL but not to lipid-poor apoA-I (Wang et al., 2004). 
ABCG5 and ABCG8, which function as heterodimers, have been identified to pro-
mote cholesterol excretion from the liver to the bile duct and the export of absorbed 
dietary sterols back to the gut lumen (Berge et al., 2000; Lee et al., 2001). 
S c a v e n g e r  r e c e p t o r  c l a s s  B  t y p e  I  
Scavenger receptor class B type I (SR-BI) mediates cholesterol efflux from macro-
phages to HDL3 (Acton et al., 1996; Ji et al., 1997; van der Velde & Groen, 2005) as 
well as selective uptake of HDL-associated cholesteryl esters and unesterified cho-
lesterol by the liver (Trigatti et al., 2003). It has been shown in vivo that modulation 
of hepatic SR-BI expression regulates the rate of cholesterol efflux from macro-
phages and the sterol excretion in the feces (Zhang et al., 2005). Mice overexpress-
ing SR-BI in the liver had reduced plasma HDL cholesterol levels and increased 
macrophage-derived sterol excretion in the feces, whereas mice deficient in SR-BI 
had increased plasma HDL cholesterol levels and markedly reduced macrophage-
derived sterol excretion in the feces, suggesting that hepatic SR-BI expression regu-
lates the rate of RCT inversely to its effect on plasma HDL cholesterol levels and 
that the rate of RCT cannot be predicted based only on measurement of plasma HDL 
cholesterol. In addition to the important role of SR-BI in RCT, it has also been iden-
tified to mediate cholesterol transport to steroidogenic tissues for steroid hormone 
synthesis. Besides SR-BI, several other cell surface receptors and HDL-binding 
proteins on hepatocytes as well as on intestinal mucosal cells, fibroblasts, and adipo-
cytes have been shown to bind HDL (Fidge, 1999).  
2.3 Interactions of apolipoproteins with lipid transfer proteins and 
lipolytic enzymes 
Besides the important role as lipid transporters, exchangeable apolipoproteins also 
play many other roles within the body. They mediate lipoprotein uptake in the liver 
and other tissues and function as co-factors for plasma enzymes and lipid transfer 
proteins. Recently, apoE has been shown to mediate lipid antigen presentation to T 
cells (van den Elzen et al., 2005). The ability of apolipoproteins to interact with 
lipids plays a central role in these functions. All soluble apolipoproteins contain 
amphipathic helixes of 11 or more residues that associate with lipid surfaces. The 
polar side of the helix faces the aqueous phase and the non-polar side the lipid sur-
face of lipoproteins (Ibdah et al., 1989; Segrest et al., 1974). The association rate of 
helical apolipoproteins with the lipid surface is dependent on the concentration ratio 
of cholesterol and phospholipids and usually occurs spontaneously at the transition 
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 temperature of phospholipids (Jonas & Mason, 1981; Pownall et al., 1979; Pownall 
et al., 1978). It has been established that the α-helical repeats are the key structural 
elements for the proper function of the apolipoproteins (Saito et al., 2004).  
The exchangeable apolipoproteins are part of a multigene family, and members of 
the A, C, and E classes of apolipoproteins share a similar genomic structure (Li et 
al., 1988). The tertiary structures of apoA-I and apoE have been shown to be related 
and share a common two-domain conformation. The amino-terminal end of both 
proteins has been shown to contain a series of amphipathic α-helical repeats, most of 
which are punctuated with prolines, while the carboxy-terminal region has been 
shown to be primarily responsible for lipid binding. The helical repeats of the N-
terminal region have been demonstrated to form a helix bundle conformation in the 
lipid-free state. Upon lipid binding the helix bundle opens, which has been shown to 
result in enhanced binding activity of apoE to its receptors such as LDLR or SR-BI. 
Respectively, the N-terminal helix of apoA-I has been shown to be critical for acti-
vation of LCAT (Saito et al., 2004).  
ApoA-I is the main protein component of plasma HDL fraction. It plays a critical 
role in reverse cholesterol transport through several actions. First, it has been shown 
to interact with the cell membrane transporter protein, ABCA1, which facilitates the 
efflux of PL and UC leading to the formation of nascent preβ-HDL particles (Oram, 
2003). Second, apoA-I has been found to serve as the most effective co-factor for 
LCAT (Fielding et al., 1972), and to adopt a belt-like arrangement in discoidal preβ-
HDL particles (Segrest et al., 1999), which has been suggested to be optimal for the 
interaction of apoA-I with LCAT (Jonas, 1991). Third, apoA-I has been reported to 
mediate the hepatic uptake of HDL cholesteryl esters by acting as a ligand for the 
cell membrane receptor SR-BI (Williams et al., 2000).  
Human apoE exists in three major isoforms, apoE2, apoE3, and apoE4, coded by 
three common apoE alleles (ε2, ε3, and ε4) of the apoE gene. The most common 
isoform, apoE3, contains a cysteine and arginine at positions 112 and 158, respec-
tively, while apoE2 contains cysteine and apoE4 arginine at both positions 
(Weisgraber et al., 1981). Similarly to apoA-I, apoE is thought to be an antiathero-
genic molecule due to its profound effect on plasma lipoprotein levels. ApoE has 
been shown to serve as a ligand not only for the LDLR (Mahley, 1988) but also to 
the LRP, the VLDL receptor, and the apoE receptor 2 (Herz & Bock, 2002). On the 
other hand, although the ε2 allele has been shown to associate with lower LDL cho-
lesterol (Sing & Davignon, 1985; Volcik et al., 2006) it has also been  shown to be 
related to type III hyperlipoproteinemia (Gregg et al., 1981; Mahley et al., 1999; 
Utermann et al., 1977), whereas the ε4 allele has been shown to associate with both 
hypercholesterolemia and type V hyperlipoproteinemia (Gregg et al., 1986; Sriniva-
san et al., 1999). In addition, apoE4 isoform of apoE has been reported to be over-
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 represented among the patients with Alzheimer’s disease (Mahley & Huang, 1999; 
Weisgraber & Mahley, 1996). 
At present, the structure-function relationships of the other members of the multi-
gene family, apoA-II, apoA-IV, apoA-V, and apoC are not so well known. Like 
apoA-I, apoA-II is a major protein component of HDL. Probably due to the hydro-
phobic nature of apoA-II, it binds lipids with high affinity and is able to displace 
apoA-I from HDL particles (Ibdah et al., 1989). Similarly to apoA-I and apoE, the 
amino acid sequence of apoA-IV is dominated by multiple α-helical repeats of 22 
residues (Li et al., 1988). However, apoA-IV lacks the hydrophobic C-terminal 
lipid-binding domain, which has been suggested to explain the low affinity of apoA-
IV for lipoproteins. Despite this, apoA-IV has been demonstrated to mimic certain 
roles of apoA-I such as activation of LCAT (Steinmetz & Utermann, 1985) and 
promotion of cholesterol efflux (Remaley et al., 2001). ApoA-V, the newest member 
of the exhangeable apolipoprotein family, has recently been identified as an impor-
tant regulator of plasma triglyceride concentration (Pennacchio et al., 2001), while 
the members of class C apolipoproteins have been reported to display both inhibi-
tory and stimulatory effects on several plasma enzymes and lipid transfer proteins 
(Saito et al., 2004).  
Besides the members of the multigene family discussed above, there are two other 
major apolipoprotein genes in humans: apoD and apoB. The genomic structures of 
apoD and apoB have been shown to differ substantially from each other as well as 
from the genomic organizations of the apolipoproteins of the multigene family 
(Blackhart et al., 1986; Drayna et al., 1987). ApoD is a member of the lipocalin 
superfamily and has been shown to associate with preβ-migrating lipoprotein spe-
cies in vitro (Francone et al., 1989). It has been speculated that apoD might favor 
heme-related compounds over cholesterol or cholesteryl esters. The specific function 
of apoD, however, awaits further definition (Peitsch & Boguski, 1990). ApoB-100, 
the main protein constituent of VLDL, IDL, LDL, and Lp(a), is the largest apolipo-
protein and shares a common amino-terminal sequence with apoB-48, the apolipo-
protein of CM (Chen et al., 1987; Powell et al., 1987). Among all apolipoproteins, 
apoB-100 has been most clearly associated with the progression of atherosclerotic 
diseases (Sniderman et al., 1980). 
2.3.1 Lipid transfer/lipopolysaccharide-binding protein family 
Several HDL apolipoproteins are able to enhance the transfer reaction of cholesteryl 
ester transfer protein (CETP). The interactions between different apolipoproteins 
and CETP have been studied intensively but only a little are known about the asso-
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 ciations of apolipoproteins with the other members of the protein family: lipopoly-
saccharide-binding protein (LBP), bactericidal permeability-increasing protein 
(BPI), and phospholipid transfer protein (PLTP), which is discussed in detail in the 
following chapter.  
C h o l e s t e r y l  e s t e r  t r a n s f e r  p r o t e i n  
Cholesteryl ester transfer protein (CETP) is a 74 kilodalton (kDa) glycoprotein, 
which plays a crucial role in lipoprotein metabolism. The C-terminal region of 
CETP contains a highly hydrophobic neutral lipid-binding domain (Albers et al., 
1984; Tall et al., 1983). CETP mediates the transfer and exchange of cholesteryl 
esters, triglycerides, and phospholipids but unlike PLTP, it is incapable of transfer-
ring phospholipids from phosphatidylcholine-containing liposomes to HDL3 
(Lagrost et al., 1994a). Furthermore, CETP and PLTP have been reported to show 
no overlap in their functions in vivo (Kawano et al., 2000). It has been shown that 
stabilization of substrate lipid particles with either apoA-I, apoA-II, apoC-II, apoC-
III, apoE (Nishikawa et al., 1988) or apoA-IV (Main et al., 1996) considerably in-
creases the CETP-mediated lipid transfer activity. ApoA-I, apoA-II, and apoE have 
been demonstrated to be more potent activators of CETP than apoC-III (Ohnishi & 
Yokoyama, 1993). Furthermore, increased apoA-II concentration in HDL particles 
has been shown to result in reduced CETP-mediated transfer rate of cholesteryl es-
ters between LDL and HDL (Lagrost et al., 1994b), while the phospholipid transfer 
activity of CETP has been reported to be inhibited by a lipid transfer inhibitor pro-
tein identified as apoF (Wang et al., 1999). 
L i p o p o l y s a c c h a r i d e - b i n d i n g  p r o t e i n  
Lipopolysaccharide-binding protein (LBP) promotes the binding of lipopolysaccha-
rides (LPS) to lipoprotein particles, resulting in the neutralization of the bioactivity 
of LPS (Wurfel et al., 1994). On the other hand, LBP is also able to transfer LPS to 
CD14, a protein found both as a soluble form in the circulation and as a membrane 
bound protein on monocytes, macrophages, and neutrophils, which has been shown 
to result in enhanced cellular defense responses (Hailman et al., 1994). LBP has 
been demonstrated to interact with HDL (Ulevitch et al., 1979) and purified apoA-I 
(Vreugdenhil et al., 2001) as well as to transfer phospholipids in vitro (Yu et al., 
1997). LBP has also been reported to circulate in association with LDL and VLDL 
both in healthy and septic subjects. The association of LBP with apoB-containing 
lipoproteins was shown to enhance the capacity of LDL and VLDL to bind LPS. 
ApoB have been found to mediate the interaction between LBP and lipoproteins at 
least in part (Vreugdenhil et al., 2001).  
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 B a c t e r i c i d a l  p e r m e a b i l i t y - i n c r e a s i n g  p r o t e i n  
Unlike the other members of the lipid transfer/lipopolysaccharide-binding protein 
(LT/LBP) family, bactericidal permeability-increasing protein (BPI) is a cellular, 
membrane-anchored protein. It can be found mainly in polymorphonuclear leukocytes 
and to a lesser extent in monocytes and macrophages. BPI binds specifically and with 
high affinity to Gram-negative bacteria. It kills bacteria by increasing the permeability 
of their outer membrane as well as by activating the enzymes that degrade bacterial 
cell wall (Elsbach et al., 1979; Weiss et al., 1978). LPS has been shown to be the fac-
tor that mediates the binding of BPI to bacteria. Thus far, BPI is the sole member of 
the LT/LBP family to have its crystal structure determined (Beamer et al., 1997). The 
association of BPI with apolipoproteins is currently unknown. 
2.3.2 Lipases 
L i p o p r o t e i n  l i p a s e  
Lipoprotein lipase (LPL) plays a crucial role in lipid transport (Wang et al., 1992). It 
is anchored to the vascular endothelium in extra-hepatic tissues via the interaction 
with heparan sulphate proteoglycans (Spillmann et al., 2006). LPL hydrolyses TG 
and PL of CM and VLDL particles. To be catalytically active, LPL requires a spe-
cific co-factor, apoC-II (Havel et al., 1970; LaRosa et al., 1970). Consistent with this 
requirement, a significant accumulation of TG has been observed in patients with an 
inherited defect of the apoC-II gene (Breckenridge et al., 1978). In contrast to apoC-
II, in vitro studies have shown that apoC-III (Jackson et al., 1986; Liu et al., 2000), 
apoE (McConathy & Wang, 1989), and apoA-I (Yamamoto et al., 2003) can inhibit 
the activity of LPL. 
H e p a t i c  l i p a s e  
Hepatic lipase (HL), associated mainly with plasma membranes of liver endothelial 
cells (Kuusi et al., 1979), hydrolyses the triglycerides of IDL leading to the formation 
of LDL particles (Nicoll & Lewis, 1980). In addition, HL hydrolyses the core TG of 
HDL2 particles resulting in the formation of smaller HDL3 particles as well as preβ-
HDL particles (Barrans et al., 1994). It has no obligatory need for apoC-II or any other 
apolipoprotein to be catalytically active. However, it has been demonstrated that both 
apoA-I and apoA-II inhibit the HL-mediated lipolysis of triglycerides (Kubo et al., 
1981). Contrary to these findings, Mowri and coworkers (1992) have reported that 
HL-mediated hydrolysis of both PL and TG was more efficient when apoA-II was 
present in HDL particles. In addition, it has been reported that apoE is able to enhance 
the HL-mediated hydrolysis of HDL phospholipids (Thuren et al., 1992). 
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 E n d o t h e l i a l  l i p a s e  
Endothelial lipase (EL) is a newly identified member of the triglyceride lipase gene 
family (Hirata et al., 1999; Jaye et al., 1999). EL has been shown to display high 
phospholipase and low triglyceride lipase activity and to hydrolyze mainly phos-
pholipids of HDL particles (McCoy et al., 2002). The two major apolipoproteins of 
HDL, apoA-I and apoA-II, have been shown to regulate the binding affinity of EL to 
HDL. In addition, apoA-I and apoA-II have been reported to have a significant in-
fluence on the hydrolysis rate of HDL phospholipids. Hydrolysis has been shown to 
be greater in HDL particles containing both apoA-I and apoA-II than in particles 
containing only apoA-I. However, only minimal hydrolysis of phospholipids could 
be detected among particles containing only apoA-II. Furthermore, EL was found to 
have higher affinity for apoA-I -containing particles than particles containing both 
apoA-I and apoA-II (Caiazza et al., 2004; Jahangiri et al., 2005). 
2.3.3 Other enzymes 
L e c i t h i n : c h o l e s t e r o l  a c y l  t r a n s f e r a s e  
Lecithin:cholesterol acyl transferase (LCAT) is a plasma enzyme which catalyzes 
the formation of cholesteryl esters and lysolecithin by transferring the fatty acyl 
group at the sn-2 position of phosphatidylcholine to the hydroxyl group of choles-
terol (Glomset, 1968). LCAT is known to be activated by several plasma apolipo-
proteins, the most important being apoA-I (Fielding et al., 1972; Furukawa & Ni-
shida, 1979; Sorci-Thomas et al., 1998; Soutar et al., 1975; Yokoyama et al., 1978). 
ApoE (Chen & Albers, 1985; Steinmetz et al., 1985; Zorich et al., 1985), apoA-IV 
(Chen & Albers, 1985; Steinmetz & Utermann, 1985) and apoA-II in the presence of 
apoA-I (Chen & Albers, 1986) as well as apoC-I (Soutar et al., 1975) and apoD 
(Kostner, 1974; Steyrer & Kostner, 1988) can also act as cofactors for LCAT al-
though they are not as efficient as apoA-I in this function. Recently, the ability of 
different apoE isoforms to activate LCAT was studied and apoE2 appeared to be the 
most efficient co-factor for LCAT among the apoE isoforms (Rye et al., 2006). On 
the other hand, apoA-II, apoC-II, and apoC-III have been shown to inhibit the LCAT 
reaction by displacing apoA-I, the enzyme itself, or both from the lipid surface of 
substrate vesicles in vitro (Chung et al., 1979; Nishida et al., 1986). 
P l a t e l e t - a c t i v a t i n g  f a c t o r  a c e t y l  h y d r o l a s e  
Platelet-activating factor acetyl hydrolase (PAF-AH) is a plasma enzyme secreted 
primarily by macrophages. It regulates plasma platelet-activating factor (PAF) levels 
by removing the acetyl group from the sn-2 position of PAF resulting in the forma-
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 tion of a biologically inactive lyso-PAF. Other anti-inflammatory properties of PAF-
AH include its ability to metabolize oxidized phospholipids (Stafforini et al., 1996; 
Tjoelker et al., 1995). PAF-AH has been shown to protect LDL from oxidation in 
vitro (Subramanian et al. 1999). Most of the serum PAF-AH is associated with LDL 
and the remainder with HDL. The direct interaction between PAF-AH and apoB or 
other apolipoproteins is currently unknown. 
P a r a o x o n a s e - 1  
Paraoxonase-1 (PON1) belongs to a family of A-esterases and is secreted mainly by 
the liver. It is able to destroy oxidized lipids present in modified LDL particles, thus 
playing an important role as an antiatherogenic molecule. In addition, it hydrolyses 
active metabolites of organophosphate toxins such as paraoxon. PON1 protects HDL 
and LDL particles from oxidation by hydrolysing lipid peroxides, cholesteryl li-
noleate hydroperoxides, and hydrogen peroxides, which are the major reactive oxy-
gen species produced during inflammation (Shih et al. 1998). PON1 activity 
(Boman, 1980) as well as concentration (Blatter Garin et al., 1994) has been shown 
to correlate positively with serum HDL cholesterol, apoA-I, and apoA-II concentra-
tion. In addition, PON1 activity has also been found to correlate positively with 
serum triglyceride and apoB concentration (Saha et al., 1991) and to associate with 
HDL3 particles containing apoE and apoJ (Bergmeier et al., 2004). 
P h o s p h o l i p a s e  A 2
Phospholipase A2  (PLA2) enzymes hydrolyze phospholipids at the sn-2 position 
generating free fatty acids and lysolipids. PLA2 are widely distributed and exist in 
many isoforms (Kougias et al., 2006). Among these, secretory PLA2–II favors the 
formation of bioactive lipids such as lysophosphatidylcholine, and it has also been 
identified as an independent risk factor for coronary artery disease (Rader, 2000). 
ApoC-I has been reported to inhibit the PLA2-mediated hydrolysis of phospholipids 
(Poensgen, 1990). 
2.4 Phospholipid transfer protein (PLTP) 
Specialized lipid transfer proteins mediate the extracellular transfer of neutral lipids 
and phospholipids between different lipoproteins as well as lipoproteins and cell 
membranes. Phospholipid transfer protein (PLTP, formerly named lipid transfer 
protein II, LTP-II) was isolated from plasma in the early 1980s during the purifica-
tion of CETP (also referred to as LTP-I), the first known lipid transfer protein in 
plasma (Tall et al., 1983; Tollefson et al., 1988). The determination of the PLTP 
complementary deoxyribonucleic acid (cDNA) sequence and detailed characteriza-
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 tion of the gene structure revealed that PLTP shares significant sequence homology 
with human CETP, LBP, and BPI (Day et al., 1994; Tu et al., 1995a). PLTP is a 
multifunctional player in lipoprotein metabolism and reverse cholesterol transport 
known to promote the exchange and transfer of phospholipids between TG-rich 
lipoproteins and HDL during lipolysis (Tall et al., 1985; Tollefson et al., 1988). As a 
consequence, HDL particles become rich in phospholipids and can accommodate 
more cholesterol for esterification by LCAT (Jonas, 1991). PLTP is also found to 
interact with a cell membrane transporter protein, ABCA1, and enhance the choles-
terol efflux from peripheral cells (Oram et al., 2003). In addition, PLTP has been 
shown to modulate HDL particle size and composition, thus generating preβ-HDL 
particles, a process known as HDL conversion (Jauhiainen et al., 1993; Tu et al., 
1993). These functions are suggested to represent antiatherogenic properties of 
PLTP. On the other hand, PLTP may be proatherogenic as it has been found to be 
present in human atherosclerotic lesions (Desrumaux et al., 2003; Laffitte et al., 
2003; O'Brien et al., 2003) as well as to facilitate the secretion of apoB-containing 
lipoproteins from hepatocytes (Jiang et al., 2001; Lie et al., 2002). As PLTP in hu-
man plasma exists in two different forms (Oka et al., 2000a), the challenge for future 
is to reveal whether the inactive form, encompassing over 50% of the total protein 
mass and incapable of transferring phospholipids, has a physiological role in lipid 
and lipoprotein metabolism. 
2.4.1 Molecular characteristics of PLTP 
P L T P  p r o t e i n  s t r u c t u r e   
Plasma phospholipid transfer protein is a serum glycoprotein that has over 40% 
hydrophobic amino acids. Its apparent molecular mass is 80 kDa. Human PLTP 
shares 93% sequence homology with pig (Pussinen et al., 1997b) and 83% homol-
ogy with mouse PLTP (Albers et al., 1995; Jiang & Bruce, 1995). PLTP cDNA 
sequence, 1750 base pairs in length, contains an open reading frame of 1518 nucleo-
tides followed by a 3’-untranslated region of 184 nucleotides (Day et al., 1994). The 
cDNA encodes a mature protein of 476 amino acids and a preceding signal sequence 
of 17 amino acids. Most of the mature protein is coded by the exons 3 to 15. A puta-
tive heparin binding domain is located within exon 12 (Tu et al., 1995a). The calcu-
lated molecular mass of the mature protein is 54719 Da. The discrepancy between 
the predicted molecular mass (55 kDa) and the 80 kDa protein mass estimated by 
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is mainly 
due to glycosylation. Besides numerous potential O-glycosylation sites, six potential 
N-glycosylation sites at amino acids 47, 77, 100, 126, 228, and 381 can be predicted 
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 from the PLTP sequence of the mature protein (Day et al., 1994).  The presence of 
abundant N-glycans and importance of N-glycosylation for PLTP secretion have 
been shown in stably transfected inducible HeLa cells (Huuskonen et al., 1998). 
Similar results have been obtained in COS-7 cells also demonstrating that no single 
glycosylation site is required for PLTP secretion (Qu et al., 2006). 
PLTP has also the potential to form two intramolecular disulfide bonds due to the 
four cysteines at residues 5, 129, 168, and 318. The Cys129 and Cys168 are essential 
for the stability and proper function of PLTP (Huuskonen et al., 1999). These two 
cysteines, which correspond to Cys135 and Cys175 in BPI, are conserved among all 
known members of the LT/LBP family (Day et al., 1994; Qu et al., 1999), while the 
two other cysteines of PLTP at residues 5 and 318 are not conserved within the gene 
family (Beamer et al., 1997). However, the importance of the Cys5 for correct fold-
ing and secretion of pig PLTP has been demonstrated (Pussinen et al., 1997b). 
The structure of PLTP has been modeled based on the three-dimensional structure of 
BPI (Beamer et al., 1997) and sequence alignments of the entire protein family 
(Huuskonen et al., 1999). According to this model, PLTP is suggested to have a 
boomerang-shaped two-domain structure (Figure 3). Each domain contains a hydro-
phobic lipid-binding pocket, which was shown to be essential for the phospholipid 
transfer activity of PLTP. The N-terminal pocket is suggested to have a more central 
role in phospholipid transfer, while the C-terminal pocket is suggested to play a 
significant role in the interaction between PLTP and HDL (Huuskonen et al., 1999). 
In accordance with this implication, it has been revealed by site-directed mutagene-
sis of charged amino acids that mutations in the N-terminal pocket significantly 
decrease the lipid transfer activity of PLTP without affecting HDL binding, whereas 
amino acid substitutions in C-terminal pocket result both in reduced HDL binding 
and decreased lipid transfer activity of PLTP (Ponsin et al., 2003). Two distinct 
basic amino acid residues of PLTP, Arg218 and Arg245, might mediate the electro-
static interaction of PLTP with negatively charged groups of HDL and other lipopro-
teins. This is supported by the finding that these two basic amino acid residues at the 
N-terminal pocket are conserved among the entire protein family and correspond to 
Lys233 and Arg259 of CETP (Jiang et al., 1995), which was first demonstrated to bind 
lipoproteins via electrostatic and hydrophobic interactions (Masson et al., 1996; 
Nishida et al., 1993). More recently, it has been reported that a cluster of hydropho-
bic residues exposed at the N-terminal tip of the PLTP molecule substitutes for the 
positively charged LPS-binding region found on the surface of LBP and BPI, and is 
critical for the interaction of PLTP with HDL. These data indicate that at least two 
distinct HDL-binding sites exist on PLTP and the binding may involve both electro-
static and hydrophobic interactions (Desrumaux et al., 2001). 
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Figure 3. The structural model of human PLTP. The α helices are shown as red cylinders, 
the β strands as yellow arrows, and the phosphatidylcholine molecules as black sticks. The
amino acid F464 is suggested to have a significant role in PLTP-mediated phospholipid 
transfer as well as in maintaining the proper conformation of the C-terminal tail of the pro-
tein (Huuskonen et al., 1999). Reproduced with the permission of The American Society for
Biochemistry and Molecular Biology. 
P L T P  g e n e  s t r u c t u r e  a n d  r e g u l a t i o n  
PLTP belongs to the LT/LBP family together with LBP, BPI, and CETP (Day et al., 
1994). PLTP shares 24% sequence homology with human LBP and 26% homology 
with human BPI (Day et al., 1994). The PLTP gene has been mapped to chromo-
some 20q12-q13.1 (Whitmore et al., 1995) and both the LBP and BPI genes to 
chromosome 20q11.23-q12 (Gray et al., 1993), whereas the CETP gene has been 
mapped to chromosome 16q12-q21 (Lusis et al., 1987). The exon-intron organiza-
tions of the genes for human PLTP, LBP, BPI, and CETP are highly conserved 
(Hubacek et al., 1997; Tu et al., 1995a). In addition, PLTP has identical number of 
amino acids as CETP and shares 20% sequence homology with it. Both PLTP and 
CETP genes have 16 exons, and the corresponding exons are similar in size. In addi-
tion, eight out of fifteen exon-intron junctions are located at the same amino acid 
residues. Although PLTP shares somewhat higher sequence homology with LBP 
and BPI, it is functionally more similar to CETP as both of these proteins facilitate 
the transfer of lipids between lipoproteins. This and the similar genomic organiza-
tion suggest that the PLTP and CETP genes evolved from a common ancestral gene 
(Tu et al., 1995a). 
The transcription process for the human PLTP gene may be initiated at several loca-
tions as four transcriptional initiation sites have been mapped at positions -75,  
-76, -77, and -80 with respect to the translational starting codon. The functional 
promoter region of the gene coding for human PLTP consists of a TATA box, a high 
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 GC region, and multiple consensus sequences for the potential binding of several 
transcription factors, which appear to be of the ubiquitous type. These include Sp1, 
AP-2, AP-3, CCAAT/enhancer-binding protein (C/EBP), and nuclear factor kappa 
immunoglobulin enhancer-binding protein (NF-kB) (Tu et al., 1995b). In addition, 
several potential binding sites for peroxisome proliferator activated receptor (PPAR) 
and sterol regulatory element binding protein (SREBP) have been found (Tu & 
Albers, 1999). The response elements for NF-kB suggest that lipopolysaccharide 
could regulate the expression of the human PLTP gene (Jiang & Bruce, 1995; Sen & 
Baltimore, 1986). On the other hand, the presence of both SREBP and SP-1 recogni-
tion motifs within DNA sequences between -769 and -719 in the human PLTP gene 
implies that cholesterol or lipoproteins via SREBP may regulate PLTP transcription. 
In addition, bile acids and the farnesoid X-activated receptor (FXR) have been re-
ported to enhance the expression of PLTP gene (Urizar et al., 2000), while the 
down-regulation of the human PLTP gene by fibrate is suggested to occur via PPAR 
regulatory pathway (Tu & Albers, 1999). More recently, the liver X receptors (LXR) 
and the heterodimer of LXR and retinoid X receptor have been shown to induce 
PLTP expression in macrophages (Cao et al., 2002; Desrumaux et al., 2003; Laffitte 
et al., 2003). In mice, the apoF gene and the gene encoding for FXR, Nr1h4, have 
been suggested to be the candidate genes located within one of the five identified 
loci involved in the regulation of PLTP activity (Korstanje et al., 2004). 
The DNA sequence between -230 and -159 relative to the first transcriptional initia-
tion site is suggested to be responsible for the full promoter activity. The potential 
binding sites for glucocorticoid receptor, Sp1, and AP-2 are located within this re-
gion (Tu et al., 1997b). However, mutagenesis of the response elements for PPAR 
and C/EBP at -322 to -299 caused reduced promoter activity of the PLTP gene, 
which may indicate the importance of these transcription factors for the regulation of 
the human PLTP gene transcription (Tu & Albers, 1999). In addition, no single re-
gion within the gene promoter is fully responsible for the promoter activity but sev-
eral DNA sequences seem to be crucial for the basal transcription of the human 
PLTP gene (Tu et al., 1995b; Tu et al., 1997b).  
Genetic variation of the human PLTP gene has been reported. In a Finnish popula-
tion study, nucleotide changes at four sites were observed in the promoter region of 
the PLTP gene. In addition, two other polymorphisms causing amino acid changes 
Phe2Leu and Arg121Trp were identified. However, none of the polymorphisms af-
fected the serum phospholipid transfer activity (Tahvanainen et al., 1999). In a 
population study of French Canadians, intronic variants of the PLTP gene have been 
found to associate with obesity-related phenotypes. However, no polymorphism was 
found within the promoter or the coding regions of the PLTP gene (Bosse et al., 
2005). On the other hand, a number of sequence anomalies within the transcribed 
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 region of PLTP gene have been identified in a population study carried out in USA, 
and variation in the PLTP gene has been demonstrated to impact disorders of HDL 
metabolism. A polymorphism in exon 1 of PLTP, the c.-34G>C minor allele, has 
been shown to associate with antiatherogenic changes in HDL cholesterol, TG, and 
their ratio. Furthermore, a missense mutation of the Arg235 has been observed to 
result in decreased PLTP activity (Aouizerat et al., 2006). 
P L T P  t i s s u e  e x p r e s s i o n  
Numerous human cell types and tissues express PLTP mRNA. The highest expres-
sion levels have been detected in the ovary, thymus, and placenta. Moderate levels 
of PLTP mRNA have been found in the pancreas, small intestine, testes, lung, and 
prostate. In the kidney, liver, and spleen the mRNA expression was found to be low 
and even lower in the heart, colon, skeletal muscle, leukocytes, and brain (Albers et 
al., 1995). This indicates that PLTP expression is locally regulated within each tis-
sue type. Relatively high concentrations of PLTP mRNA detected in the ovary, pla-
centa, testes, and prostate may suggest that PLTP plays a role in reproduction and 
fetal development. It has also been speculated that expression of PLTP in the lung 
might have an important role in maintaining normal function of this organ. In a 
mouse model for emphysema as well as in emphysematous patients, PLTP mRNA 
expression has been reported to be 3- to 4-fold higher than in the control subjects 
indicating that a hypoxic stimulus occurring in emphysema may contribute to the 
enhanced PLTP gene expression (Jiang et al., 1998). Recently, PLTP has been 
shown to play a key role in sperm motility and male fertility in a mouse model 
(Drouineaud et al., 2006). The expression of PLTP mRNA in small intestine and 
enhanced secretion of the protein during postprandial conditions may have a signifi-
cant role as PLTP facilitates the transfer of phospholipids from triglyceride-rich 
lipoproteins to HDL during lipolysis. In spite of low expression level of PLTP 
mRNA in the liver, it could still be a major contributor to the plasma PLTP concen-
tration due to its large organ mass (Albers et al., 1995). In human plasma, PLTP 
circulates mainly together with larger HDL2 particles (Speijer et al., 1991), and its 
concentration has been estimated to be 4-15 mg/l (Desrumaux et al., 1999a; Huus-
konen et al., 2000a; Oka et al., 2000b). Recently, PLTP-mediated PL transfer activ-
ity has also been detected in human tear fluid (Jauhiainen et al., 2005). 
The tissue expression of PLTP mRNA varies between species. The tissue distribu-
tion of mouse and pig PLTP mRNA has been reported to be similar and to differ to 
some extent from the human mRNA distribution. Unlike the human brain tissue, 
relatively high levels of PLTP mRNA have been detected both in the mouse and pig 
brain. In addition, relatively high expression levels of PLTP mRNA have been de-
tected in human placenta, intestine, and kidney, while in the corresponding mouse or 
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 pig tissues the expression levels were low (Albers et al., 1995; Day et al., 1994; 
Pussinen et al., 1997b).  
H i g h -  a n d  l o w - a c t i v i t y  f o r m s  o f  P L T P  
The development of the methods for determining PLTP concentration (Desrumaux 
et al., 1999a; Huuskonen et al., 2000a; Oka et al., 2000b) revealed that PLTP exists 
in human plasma in two different forms, one with high activity (HA-PLTP) and the 
other with low activity (LA-PLTP) (Oka et al., 2000a). However, the estimates of 
the relative concentrations of the HA- and LA-PLTP in human plasma vary. This 
has been suggested to be due to different reactivities of the antibodies used in mass 
assays against the two PLTP forms (Murdoch et al., 2002b). 
Only one gene has been reported to code for both forms of the protein indicating that 
the regulation of PLTP activity occurs at the post-translational level. The two PLTP 
forms in human plasma have been shown to associate with distinct macromolecular 
populations. In size-exclusion chromatography, PLTP activity has been demonstrated 
to elute with an average mass of 160 kDa, whereas the low-activity form of PLTP has 
been shown to elute in a position corresponding to a molecular size of 520 kDa (Oka 
et al., 2000a). In plasma of mice expressing human PLTP, two populations of PLTP 
have also been observed. One population has been shown to have low specific activity, 
whereas the other population displayed high specific activity (Jaari et al., 2001). Fur-
thermore, PLTP secreted by human hepatoma cell line, HepG2, has been shown to 
resemble the high-activity form of PLTP found in human plasma. Similarly to HA-
PLTP in human plasma, PLTP purified from HepG2 cell medium has been found to 
elute in size-exclusion chromatography at the position corresponding to a molecular 
size of 160 kDa. In addition, PLTP has been demonstrated to co-elute with apoE but 
not with apoA-I or apoB-100, and the activity could be inhibited only with antibodies 
against PLTP or apoE (Siggins et al., 2003). Contrary to earlier findings, in the study 
of Cheung and Albers (2006), active PLTP was found to associate primarily with 
apoA-I but not with apoE-containing lipoproteins when detected directly from the 
plasma samples without a prior purification of the two PLTP forms. 
2.4.2 Functions of PLTP 
L i p i d  t r a n s f e r  
PLTP is a non-specific lipid transfer protein that preferentially transfers phospholip-
ids between different lipoproteins (Massey et al., 1985). The bulk of PLTP-mediated 
phospholipid transfer most probably occurs between HDL particles as 89 mol % of 
lipoproteins in men and 94 mol % of lipoproteins in women are HDL (Smith et al., 
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 1983). Unlike CETP, PLTP is unable to transfer neutral lipids although the C-
terminal end of the protein is somewhat hydrophobic. It has been shown, however, 
that PLTP is able to enhance the CETP-mediated transfer of cholesteryl esters be-
tween HDL3 and LDL or VLDL (Lagrost et al., 1994a; Tollefson et al., 1988). 
PLTP-mediated PL transfer is suggested to occur through protein and lipoprotein bi- 
or trimolecular collisions (Rao et al., 1997) and without formation of a tight com-
plex with phospholipids (Huuskonen et al., 1996). In addition, the electric charge of 
lipoproteins has been shown to influence the activity of the human plasma PLTP 
suggesting that the interaction of PLTP with lipoproteins is electrostatic. The effect 
of lipoprotein surface potential on the activity of PLTP was found to be similar to 
that of CETP. The optimal surface potential value of HDL particles for maximal 
transfer rate of PLTP was observed to be -11.6 mV (Desrumaux et al., 1998). 
PLTP has been shown to transfer a variety of lipids with two acyl chains and a polar 
head group (Huuskonen et al., 1996; Rao et al., 1997). The most preferred substrate 
was found to be diacylglycerol followed by phosphatidic acid, sphingomyelin, phos-
phatidylcholine, phosphatidylglycerol, cerebroside, and phosphatidyl-ethanolamine. 
Increase in acyl chain length from 16 or 18 to 20 methylenes or decrease from 10 to 6 
methylenes has been shown to associate with slower PLTP-mediated transfer rates, 
whereas unsaturation of one acyl chain of phosphatidylcholine molecule greatly en-
hanced the transfer by PLTP. The exchange of unsaturated fatty acids between sn-
1/sn-2 positions was observed to have only small effects on PLTP transfer rate. In 
addition, PLTP was shown to transfer phosphatidylcholine less efficiently from reas-
sembled HDL that were small in size or with high UC content (Rao et al., 1997). The 
latter may be explained by a competition reaction as it has been reported that PLTP is 
also capable of transferring unesterified cholesterol (Nishida & Nishida, 1997).  
Varying levels of PLTP activity can be detected in plasmas of several vertebrate 
species. The activity levels in mouse and rat have been reported to be higher than in 
humans, while in rabbit and guinea pig the activity was significantly lower than in 
humans. In hamster, dog, pig, and monkey PLTP activity was comparable to the 
levels detected in human plasma (Cheung et al., 1996). On the other hand, in the 
study of Speijer and coworkers (1991), rat was reported to have considerably lower 
activity levels as compared to humans. Furthermore, it has been reported that ani-
mals such as chicken, pig, rabbit, and man, which are relatively susceptible for 
atherogenesis, display lower mean PLTP activity than animals such as cat, dog, 
mouse, and rat, which in turn can resist the progression of atherosclerotic diseases 
more effectively (Guyard-Dangremont et al., 1998). 
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 H D L  c o n v e r s i o n  
PLTP is an important mediator of HDL metabolism, having a considerable impact 
on the heterogeneity of circulating HDL and especially on the generation of preβ-
HDL particles simultaneously with large-sized HDL. PLTP and CETP have been 
shown to have opposite effects on HDL size distribution as PLTP promotes the for-
mation of HDL2b particles at the expense of HDL3a, whereas CETP increases the 
relative proportion of both HDL3b and HDL3c at the expense of HDL2a (Lagrost et 
al., 1996). On the other hand, PLTP has also been shown to be capable of promoting 
the formation of preβ-HDL particles from HDL2 (Marques-Vidal et al., 1997). In 
fluorescence spectroscopic measurements, PLTP has been shown to promote mixing 
of cholesteryl esters in the core of reassembled HDL particles (Lusa et al., 1996) 
indicating that the remodeling of HDL particles occurs through a particle fusion 
process (Albers et al., 1995; Jauhiainen et al., 1993; Lusa et al., 1996; Settasatian et 
al., 2001; Tu et al., 1993; von Eckardstein et al., 1996), which has also been demon-
strated by 1H NMR spectroscopy (Korhonen et al., 1998). According to the hypothe-
sis of Settasatian and coworkers (2001), the initial event in HDL3 particle conver-
sion involves interaction of PLTP with the phospholipid surface of HDL particles, 
which induces an increase in the surface pressure either due to increased lipid con-
centration on the particle surface or penetration of PLTP into the lipid monolayer. 
This, in turn, causes fusion of HDL particles and formation of an unstable large 
particle that rearranges into small particles each containing two  
apoA-I molecules (Figure 4). Alternatively, the unstable fusion particle could rear-
range into a more stable, large fusion product containing four apoA-I molecules with 
a concomitant dissociation of lipid-free or lipid-poor apoA-I molecules. In accor-
dance with this hypothesis, it has been shown that PLTP-mediated HDL conversion 
is dependent on efficient phospholipid transfer (Huuskonen et al., 2000b). 
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 Triglyceride enrichment of HDL has been reported to enhance HDL remodeling by 
PLTP (Rye et al., 1998), while oxidative modifications of HDL impair the PLTP-
mediated HDL conversion (Pussinen et al., 2003). Enhanced conversion of TG-rich 
HDL particles has been suggested to be due to the destabilization of apoA-I in TG-
rich HDL (Settasatian et al., 2001). In addition, a hydrophobic cluster in the N-
terminal end of PLTP has been shown to be critical for the conversion activity of the 
protein (Desrumaux et al., 2001). The molar ratio of apoA-I and apoA-II in HDL 
particles has been reported to have an influence on PLTP-mediated HDL conversion 
(Albers et al., 1995). PLTP has been reported to have a distinctly different effect on 
the HDL subpopulations containing only apoA-I or both apoA-I and apoA-II. The 
difference could be observed in the size distribution of these subpopulations after the 
interconversion by PLTP. Larger average size of fusion particles were observed 
1.
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Figure 4. A model for PLTP-mediated remodeling of HDL.  The formation of a ternary colli-
sion complex of two HDL3 particles, each of which contain three molecules of apoA-I, and of 
one boomerang-shaped PLTP molecule (1) leads to a fusion of HDL3 particles and  subsequent 
formation of a large unstable particle with six molecules of apoA-I (2). The fusion product 
either rearranges into three small particles each containing two apoA-I molecules (3) or is con-
verted into a large, more stable fusion particle with a concomitant dissociation of two lipid-free 
or lipid-poor apoA-I molecules (4). Adapted from Settasatian et al., 2001. 
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 among a subpopulation containing only apoA-I. Also, increasing concentrations of 
apoA-II in HDL have been shown to result in impaired remodeling of HDL by 
PLTP, and the conversion was found to be totally inhibited when HDL particles 
contained only apoA-II. This suggests a significant role for apoA-I in the HDL con-
version process (Lusa et al., 1996; Pussinen et al., 1997a).  
Besides human recombinant or plasma-derived PLTP, also mouse and pig recombi-
nant or plasma-derived PLTP, respectively, has been shown to promote HDL inter-
conversion in vitro (Albers et al., 1995; Pussinen et al., 1995). This suggests that 
PLTP may function similarly in these species. Furthermore, the results from experi-
mental studies with mice transgenic for the human apoA-I gene and overexpressing 
human PLTP demonstrate that PLTP facilitates HDL conversion also in vivo 
(Ehnholm et al., 1998). 
O t h e r  f u n c t i o n s  
PLTP has been found to enchance cholesterol efflux from peripheral cells and the 
uptake of cholesterol by preβ-HDL (von Eckardstein et al., 1996) as well as by HDL 
particles with electrophoretic mobility between alpha and preβ (Wolfbauer et al., 
1999). This has been shown to occur through an interaction of PLTP with a cell 
membrane transporter protein, ABCA1 (Oram et al., 2003). In accordance with this, 
endogenous PLTP synthesized by macrophage foam cells has been shown to have a 
significant contribution to the ABCA1-mediated cholesterol efflux in these cells 
(Lee-Rueckert et al., 2006). In addition, macrophage-derived PLTP has been ob-
served to inhibit the development of atherosclerotic lesions in hyperlipidemic mice, 
whereas PLTP deficiency was observed to result in significantly smaller concentra-
tions of vitamin E and increased oxidative stress of macrophages, thus suggesting an 
antiatherogenic role for PLTP within the vessel wall (Valenta et al., 2006). 
In addition, it has been suggested that PLTP could display inherent protease activity 
on apoA-I. The cleaveage has been demonstrated to occur in the C-terminal end of 
apoA-I, between the residues Ala196 and Thr197 (Jauhiainen et al., 1999). However, 
the effect of PLTP-mediated proteolysis of apoA-I on RCT has not been elucidated. 
On the other hand, mast cell chymase has been shown to degrade both PLTP and 
preβ-HDL particles generated by PLTP in vitro (Lee et al., 2003). Furthermore, mast 
cell chymase has also been shown to degrade apoA-II and apoE in mouse plasma 
deficient for apoA-I, which has been shown to result in impaired cholesterol efflux 
from macrophage foam cells (Lee et al., 2002). 
Besides lipoprotein metabolism, PLTP may also play a role in antimicrobial defense 
and maintenance of the antioxidant status of cells. In addition to lipids, plasma 
PLTP facilitates the transfer of some other amphipathic molecules, such as lipopoly-
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 saccharides (Hailman et al., 1996) and α-tocopherol (Kostner et al., 1995), between 
lipoproteins as well as between lipoproteins and cells. HDL and other plasma lipo-
proteins are important neutralizers of the bioactivity of LPS, a membrane lipid of 
Gram-negative bacteria. PLTP has been shown to release LPS from Gram-negative 
bacterial membranes when HDL particles are present, thus reducing the host immu-
nological responses to LPS (Vesy et al., 2000). Unlike LBP or soluble CD14, PLTP 
is incapable of enhancing the release of LPS from monocyte cell surface (Kitchens 
et al., 1999). It has been reported, however, that PLTP is able to neutralize the bio-
logical activity of LPS simply by binding it, thus preventing its recognition by solu-
ble or membrane bound CD14 or other cellular receptors. Also, PLTP was found to 
inhibit interleukin-6 production in response to LPS (Hailman et al., 1996). On the 
other hand, injection of LPS into mice has been shown to cause a significant de-
crease both in PLTP activity and mRNA expression in the lung, adipose tissue, and 
liver (Jiang & Bruce, 1995). 
The most potent antioxidant form of vitamin E, α-tocopherol, is secreted from the 
liver into the bloodstream and transported by lipoproteins in the plasma compart-
ment. It has been demonstrated that PLTP promotes the transfer of α-tocopherol 
from HDL to oxidized LDL, suggesting an important role for PLTP in restoring the 
antioxidant profile of plasma LDL particles, hence hindering the development of 
atherosclerosis (Desrumaux et al., 1999b). In addition, PLTP was shown to sustain 
the endothelium-dependent arterial relaxation by supplying endothelial cells with α-
tocopherol. Furthermore, PLTP deficiency has been shown to result in significant 
depletion of brain α-tocopherol producing a chronic and moderate oxidative stress 
and increased anxiety in both homozygous and heterozygous PLTP deficient mice 
(Desrumaux et al., 2005). On the other hand, PLTP deficiency (PLTP-/-) has been 
demonstrated to result in increased vitamin E content of VLDL and LDL, thereby 
protecting them from oxidation (Jiang et al., 2002). PLTP has also been proposed to 
facilitate the transfer of amphotericin B, an antibiotic used in the treatment of sys-
temic fungal infections, to HDL (Patankar & Wasan, 2006). 
2.4.3 Factors affecting PLTP activity and concentration 
D i e t - d e r i v e d  a n d  p e r s o n a l  a t t r i b u t e s  
In obese individuals, PLTP activity has been observed to be elevated. PLTP activity 
has been shown to correlate positively both with body mass index (BMI) and waist-
to-hip circumference ratio (WHR) (Cheung et al., 2002; Dullaart et al., 1994b; Kaser 
et al., 2001; Murdoch et al., 2000; Tahvanainen et al., 1999). Decreased PLTP activ-
ity upon diet-induced weight loss has been shown to associate with changes in sub-
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 cutaneous fat and free fatty acids (Murdoch et al., 2003). In obese women, a short-
term weight loss has been shown to result in a concomitant and parallel reduction in 
PLTP and CETP concentrations (Tzotzas et al., 2006). Furthermore, weight loss 
after gastric banding surgery has been demonstrated to result in a significant de-
crease in PLTP activity as well as increased HDL2 particle size (Kaser et al., 2004). 
The influence of dietary lipids on PLTP activity has been studied quite intensively. 
When compared with a dairy fat-based diet, PLTP activity and HDL cholesterol 
concentration have been shown to reduce significantly during a stearic acid diet, 
whereas diet enriched in unsaturated fatty acids with trans double bonds had no 
influence on PLTP activity despite reduced HDL cholesterol levels (Aro et al., 
1997). In normolipidemic men and women consuming a lauric acid diet, PLTP ac-
tivity was found to be higher than in subjects consuming diet enriched in palmitic 
acid. This indicates that also the chain length of saturated fatty acids modulates se-
rum PLTP activity. The influence of oleic acid diet was reported not to differ sig-
nificantly from the influences of saturated diets on PLTP activity (Lagrost et al., 
1999b).  Cholesterol feeding has been shown to result in significant rises in both 
PLTP and CETP activities in rabbits (Meijer et al., 1993). As in rabbits, high fat and 
high cholesterol diet increased serum phospholipid transfer activity in mice, which 
was also associated with increased PLTP mRNA levels in the lung, suggesting that 
elevated plasma lipid concentration regulates PLTP expression (Jiang & Bruce, 
1995; Tu et al., 1999). Consistent with these findings, a large intravenous fat load 
has been shown to stimulate plasma PLTP activity in healthy men (Riemens et al., 
1999a). However, after administration of a single fatty meal containing moderate 
amounts of cholesterol, PLTP activity has been reported to remain unchanged in 
normolipidemic men (Syeda et al., 2003). In addition, PLTP activity has been shown 
to correlate positively with serum triglyceride concentration (Tahvanainen et al., 
1999). High amounts of the cholesterol-raising diterpenes, cafestol and kahweol, 
which are present in unfiltered coffee, have been shown to significantly increase 
serum PLTP activity (van Tol et al., 1997). 
Moderate alcohol consumption has been shown to correlate negatively with CAD 
(Rimm et al., 1991) and positively with plasma HDL levels (Castelli et al., 1977). 
Among alcohol abusers, plasma PLTP activity has been observed to be significantly 
higher than in the control subjects (Liinamaa et al., 1997). In addition, in alcoholic 
patients, PLTP activity has been reported to reduce significantly after alcohol with-
drawal (Lagrost et al., 1996) with a concomitant shift of HDL particle size towards 
smaller particles (Taskinen et al., 1982; Välimäki et al., 1993). Furthermore, ele-
vated HDL cholesterol associated with moderate alcohol consumption has been 
reported not to be related to altered plasma PLTP, CETP or LCAT activity levels 
(Riemens et al., 1997). 
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 Besides dietary lipids and alcohol consumption, smoking has been reported to influ-
ence PLTP activity. Among normolipidemic men, smoking has been shown to im-
pair several steps in the RCT process. In the fasting (Zaratin et al., 2004) or post-
prandial state (Mero et al., 1998), smoking has been shown to result in reduced ac-
tivities of several plasma enzymes and lipid transfer proteins including PLTP, 
CETP, and HL. Concerning the plasma lipid transfer protein activities, opposite 
results have been reported by Dullaart and colleagues (1994a) although unfavorable 
changes in plasma lipoprotein profile were also observed in this study. 
I n f l a m m a t i o n  
PLTP activity has been reported to be elevated in patients with a systemic inflamma-
tion (Barlage et al., 2001) or a severe acute-phase response (Pussinen et al., 2001b). 
PLTP mass, on the other hand, has been found to be significantly lower in patients 
with acute-phase response than in the control subjects (Pussinen et al., 2001b) de-
spite the finding that during the acute phase response, the synthesis of several 
plasma glycoproteins is increased in the liver (Mookerjea et al., 1983). Also, in an 
experimental study, PLTP-mediated remodeling of acute-phase HDL3 particles has 
been demonstrated to be more efficient than the conversion of native HDL3 particles 
despite the displacement of apoA-I by SAA. This could be explained in part by ele-
vated triglyceride content of HDL during acute phase response (Pussinen et al., 
2001a; Rye et al., 1998). Furthermore, the apoA-I of acute-phase HDL was found to 
be more prone to PLTP-mediated degradation (Jauhiainen et al., 1999), which may 
lead to accelerated catabolism of degraded apoA-I and result in decreased HDL 
levels during inflammation (Brinton et al., 1994; Brinton et al., 1991). Elevated 
PLTP activity has also been shown to be related to chronic subclinical inflammation 
in patients with type 2 diabetes (Tan et al., 2005). 
D i a b e t e s  
Patients with type 1 or type 2 (non-insulin-dependent) diabetes display elevated 
serum PLTP activity (Colhoun et al., 2002; Riemens et al., 1998b) and mass 
(Desrumaux et al., 1999a). PLTP activity has been shown to correlate with concen-
trations of small, dense LDL particles and apoE in patients with type 2 diabetes (Tan 
et al., 2003; Tan et al., 2006). Furthermore, treatment with atorvastatin has been 
shown to result in decreased PLTP activity with a concomitant decrease in apoE 
concentration (Dallinga-Thie et al., 2006). In type 2 diabetes, plasma cholesteryl 
ester transfer has been found to be elevated and associated with higher plasma PLTP 
activity levels as well as with triglyceride concentration (Riemens et al., 1998a). 
Furthermore, in subjects with type 2 diabetes or CAD, PLTP activity and HDL par-
ticles containing both apoA-I and apoA-II have been reported to be the main deter-
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 minants inducing the plasma cholesterol efflux potential from Fu5HA rat hepatoma 
cells (Syvänne et al., 1996). On the other hand, lowered plasma phospholipid trans-
fer activity and increased diacylglycerol concentration among plasma lipoproteins 
have been demonstrated among type 2 diabetic patients (Elchebly et al., 1996). The 
discrepancy between different studies has been speculated to result from the sub-
strate specificity of PLTP and favoring of diacylglycerols over phospholipids lead-
ing to a bias in PLTP activity assay measuring only transferred PL (Lalanne et al., 
1999). In non-diabetic, insulin resistant subjects, plasma PLTP activity has also been 
reported to be elevated (Riemens et al., 1999c; Van Tol et al., 1997) resulting in 
enhanced preβ-HDL formation and cellular cholesterol efflux despite lower total 
HDL levels (Dullaart & van Tol, 2001). In addition, insulin infusion has been shown 
to result in decreased PLTP activity (Riemens et al., 1999b; Riemens et al., 1999c). 
A l z h e i m e r ’ s  d i s e a s e  
Increased PLTP mRNA and protein expression in central nervous system has been 
demonstrated in patients with Alzheimer’s disease (AD) indicating a role for PLTP 
in lipid metabolism in the brain (Vuletic et al., 2003). In cell culture experiments, 
neurons, microglia, and astrocytes have been shown to synthesize and secrete active 
PLTP. In addition, the presence of PLTP also in oligodendroglia has been demon-
strated by immunohistochemistry indicating that all classes of brain cells synthesize 
PLTP. PLTP activity has been detected in cerebrospinal fluid (CSF) of neurologi-
cally healthy subjects representing approximately 15% of the plasma activity 
(Vuletic et al., 2003). However, in patients with probable AD or with other neuro-
logical diseases, PLTP activity in CSF was found to be significantly lower than in 
control subjects (Vuletic et al., 2005). In the study of Demeester and colleagues 
(2000), PLTP mass and activity in CSF of both healthy and AD subjects have been 
reported to represent only 1% of the values detected in human plasma. The differ-
ences in observed activity levels in CSF between the two studies might result from 
different methods used for determining PLTP activity. The activity in CSF was also 
shown to correlate positively with apoE concentration in both AD and control sub-
jects and to associate with apoE-containing lipoprotein particles to some extent. In 
addition, PLTP was shown to significantly enhance the secretion of apoE in primary 
human astrocytes in vitro (Vuletic et al., 2005). On the other hand, statins with dif-
fering blood-brain barrier penetrability, simvastatin and pravastatin, have been re-
ported to have different effects on CSF PLTP activity and apoE concentration in 
modestly hypercholesterolemic, cognitively intact individuals (Vuletic et al., 2006). 
Simvastatin, which penetrates blood-brain barrier, was reported to significantly in-
crease PLTP activity in CSF, while pravastatin, which does not penetrate blood-
brain barrier, had no such effect. In addition, treatment with both simvastatin and 
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 pravastatin was shown to result in lowered CSF apoE concentration, indicating that 
the statin treatment might have affected the relationship between PLTP and apoE. 
2.4.4 PLTP and atherosclerosis 
C l i n i c a l  s t u d i e s  
The role of PLTP activity in human diseases and other physiological states has been 
studied quite intensively as discussed above, while the evaluation of PLTP concen-
tration still awaits further investigation. Several studies have demonstrated a positive 
correlation between PLTP activity and HDL cholesterol (Cheung et al., 2002; Mur-
doch et al., 2000; Murdoch et al., 2002a) although opposite results have also been 
reported (Huuskonen et al., 2000a; Schlitt et al., 2003). In a prospective study of 
Japanese men, PLTP concentration was found to correlate positively with serum 
HDL cholesterol and negatively with TG, LDL cholesterol, and BMI. In addition, a 
significant, independent, and inverse relationship was reported between serum PLTP 
concentration and the risk of cardiovascular diseases (Yatsuya et al., 2004). How-
ever, PLTP activity has been shown to be positively related to the metabolism of the 
apoB-containing lipoproteins (Cheung et al., 2002; Murdoch et al., 2000; Murdoch 
et al., 2002a; Riemens et al., 1998a). Both gender and obesity-related factors have 
been suggested to modulate the effect of PLTP activity on the apoB-containing lipo-
proteins (Cheung et al., 2002). In healthy obese men or in patients with type 1 or 
type 2 diabetes, PLTP activity has been observed to be increased from 15 to 50% 
(Colhoun et al., 2002; Dullaart et al., 1994b; Riemens et al., 1998b). Moreover, in 
contrast to PLTP concentration, PLTP activity has been shown to be an independent 
risk factor for CAD (Schlitt et al., 2003). 
Results from immunohistochemistry studies have demonstrated that PLTP is highly 
expressed by macrophages and smooth muscle cells within human atherosclerotic 
lesions. Cholesterol loading of macrophages has been demonstrated to result in 2- to 3-
fold increase in both PLTP mRNA and protein expression as well as in elevated activ-
ity (Desrumaux et al., 2003; Laffitte et al., 2003; O'Brien et al., 2003). Hypoxia has 
been shown to increase PLTP mRNA expression in the lung (Jiang et al., 1998) and to 
result in the formation of TG-loaded macrophage foam cells within the atherosclerotic 
lesions (Bostrom et al., 2006), which may in part explain the enhanced expression of 
PLTP within the lesions. Furthermore, PLTP has been shown to accumulate on ex-
tracellular matrix, colocalizing with apoA-I, apoE, apoB, and the vascular proteogly-
can biglycan, to which PLTP has been observed to mediate HDL binding in vitro. This 
function of PLTP has been reported to be independent of its phospholipid transfer 
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 activity, suggesting that both the active and inactive forms of PLTP can facilitate HDL 
retention on vascular proteoglycans (O'Brien et al., 2003).  
In treatment of atherosclerosis, the most effective and commonly used agents for 
lowering LDL cholesterol and raising HDL cholesterol are statins and niacin, re-
spectively. Treatment of patients with low HDL and CAD with simvastatin-niacin 
has been shown to result in increased concentration of HDL particles containing 
apoA-I as the sole apolipoprotein. However, despite the positive relationship be-
tween PLTP activity and HDL particles containing apoA-I at baseline (Cheung et 
al., 1999), no consistent change in PLTP activity could be detected after treatment  
with simvastatin-niacin, suggesting that the drug therapy might have affected this 
relationship (Cheung et al., 2001). Furthermore, it has been suggested that simvas-
tatin treatment of patients with type IIb hyperlipidemia does not affect PLTP mass 
although a significant increase in PLTP activity has been detected in an endogenous 
lipoprotein-dependent assay. However, no change in PLTP activity could be ob-
served in an exogenous lipoprotein-independent assay among these patients (Lagrost 
et al., 1999a). Hypertriglyceridemia has been shown to result in decreased HDL 
cholesterol and PLTP mass values. Bezafibrate-induced increase in HDL choles-
terol, however, has been reported not to affect PLTP concentration. The bezafibrate 
therapy has been suggested to improve insulin resistance, and thereby lead to a de-
crease in PLTP activity (Jonkers et al., 2003). 
A n i m a l  m o d e l s  
Genetically altered mouse models have played a crucial role in elucidating the impact 
of PLTP on lipoprotein metabolism and progression of atherosclerosis. The mouse 
gene encoding phospholipid transfer protein has been mapped to chromosome 2 
(LeBoeuf et al., 1996), and the genomic organizations of both the mouse and human 
PLTP genes have been found to be similar (Tu et al., 1997a). Revealing of the mouse 
PLTP gene structure has enabled the modulation of PLTP gene expression. 
A human PLTP deficiency state has not been described, whereas in mice, PLTP 
deficiency has been shown to result in decreased plasma HDL levels independent of 
diet. In addition, in PLTP deficient (PLTP-/-) mice on a high fat diet, an increase in 
VLDL and LDL phospholipids, unesterified cholesterol, and cholesteryl esters with-
out a change in apoB concentration has also been observed. This has been reported 
to result from accumulation of IDL/LDL size vesicular lipoproteins enriched in UC 
and PL, indicating impaired transfer of surface remnants from TG-rich lipoproteins 
to HDL (Jiang et al., 1999). These accumulating lamellar lipoproteins have been 
reported to contain apoA-IV and apoE as major apolipoproteins (Qin et al., 2000). 
Hepatic lipase and SR-BI have been demonstrated to have a major role in the clear-
ance of PL and UC of these surface remnants in PLTP-/- mice (Kawano et al., 
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 2002). Experimental studies with hypercholesterolemic mice deficient of the LDL 
receptor (LDLR-/-) and with normal plasma apoA-I levels have demonstrated the 
atheroprotective role of macrophage-derived PLTP within the blood vessel wall 
(Valenta et al., 2006). In these mice, PLTP was found to inhibit lesion development, 
suggesting that pro- or antiatherogenic properties of PLTP are dependent on the site 
of protein expression and action. In addition, PLTP deficiency was demonstrated to 
result in decreased α-tocopherol content and increased oxidative stress of bone mar-
row macrophages in vitro. 
Mice expressing human PLTP have significantly higher serum HDL cholesterol and 
lower non-HDL cholesterol than wildtype mice despite similar plasma PLTP activity 
levels (Albers et al., 1996). Overexpression of human PLTP in mice, wildtype or 
transgenic for the human apoA-I gene, has been shown to result in increased forma-
tion of preβ-HDL particles (Ehnholm et al., 1998; Föger et al., 1997; Jiang et al., 
1996). Consistent with this finding, plasma of mice overexpressing human PLTP has 
been demonstrated to be more efficient in preventing the cholesterol accumulation in 
cultured macrophages than plasma of wildtype mice (van Haperen et al., 2000), 
indicating an important role for PLTP in modulating RCT in vivo. As mice by nature 
do not express CETP, the relative contribution of PLTP and CETP to the generation 
of preβ-HDL particles has been studied in mice transgenic either for human PLTP or 
human CETP or both. The results from this study have demonstrated that PLTP 
rather than CETP is responsible for the formation of preβ-HDL (Lie et al., 2001). 
Furthermore, a dramatic reduction in total HDL cholesterol and enhanced hepatic 
uptake of HDL phospholipids and cholesteryl esters as well as increased fecal bile 
acid excretion have been reported in mice with elevated PLTP activity (Ehnholm et 
al., 1998; Föger et al., 1997; Jiang et al., 1996; Post et al., 2003).  
Several experimental studies have identified plasma PLTP as a risk factor for 
atherosclerosis. It has been reported that a 2-fold increase in PLTP activity either in 
heterozygous LDL receptor-deficient (LDLR+/-) mice or in mice with apoE defi-
ciency (apoE-/-), results in moderately increased VLDL secretion, increased athero-
sclerotic lesions, decreased plasma content of vitamin E, increased lipoprotein oxi-
dation, and increased auto-antibodies against oxidized LDL (van Haperen et al., 
2002; Yang et al., 2003). However, a moderate 1.3-fold increase in PLTP activity in 
these mice has been shown not to associate with atherogenesis (Yang et al., 2003). 
In mice transgenic for human CETP, a 2.8-fold overexpression of PLTP has been 
shown to result in a 1.5-fold increase in VLDL secretion as compared to mice ex-
pressing only human CETP (Lie et al., 2002). In heterozygous LDL receptor-
deficient (LDLR+/-) mice expressing both human PLTP and human CETP genes, 
expression of PLTP has been shown to result in a dose-dependent decrease in VLDL 
and LDL cholesterol as well as in HDL cholesterol (Lie et al., 2004). However, de-
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 spite the reduction of apoB-containing lipoproteins, these mice have been found to 
display increased atherosclerotic lesion areas as well as increased number of sec-
tions containing cholesterol clefts, thus demonstrating the atheroprotective role of 
HDL cholesterol and HDL-associated antioxidative enzymes, PON1 and PAF-AH. 
On the other hand, PLTP deficiency (PLTP-/-) has been shown to associate with de-
creased secretion and plasma levels of apoB-containing lipoproteins in human apoB 
transgenic mice and in apoE-deficient (apoE-/-) mice (Jiang et al., 2001). PLTP defi-
ciency has been shown to be related to decreased liver content of vitamin E as well as 
increased hepatic oxidant concentration. Moreover, PLTP deficiency has been re-
ported to stimulate the intracellular oxidant-dependent proteolysis of newly synthe-
sized apoB (Jiang et al., 2005). In PLTP-/- and LDLR-/- mice, accumulation of vita-
min E has been reported to protect lipoproteins from oxidation and to result in lower 
atherosclerosis susceptibility despite a lack of reduction in apoB-containing lipopro-
teins (Jiang et al., 2002). Furthermore, PLTP deficiency (PLTP-/-) both in mice ex-
pressing human apoB and in LDLR-/- mice has been reported to result in higher affin-
ity of plasma HDL for oxidized phospholipids, thereby reducing the ability of LDL to 
induce monocyte chemotactic activity in vitro (Yan et al., 2004).  
PLTP has a vital role in the maintenance of plasma HDL levels. In addition, the 
ability of PLTP to generate preβ-HDL and to promote cell-surface binding of HDL 
has been shown to play an important role in enhancing flux of excess cholesterol 
from peripheral tissue cells and retarding atherogenesis. However, growing body of 
evidence suggests that inhibition of PLTP could serve as a target in the treatment of 
atherosclerosis. As PLTP has been shown to display both pro- and antiatherogenic 
properties depending on the site of protein expression and action, the overall effects 
of pharmacological modulation or inhibition of the PLTP gene on lipid and glucose 
metabolism are difficult to predict and remain a challenge for future studies. As the 
effect of CETP inhibitors on atherogenesis is now under clinical investigations 
(Okamoto et al., 2000), it is interesting to speculate, whether a phenotype of de-
creased serum apoB-lipoproteins and of normal HDL levels would result from the 
combined inhibition of CETP and PLTP in humans. 
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 3 AIMS OF THE STUDY 
 
1. To isolate and characterize the high-activity (HA) and low-activity (LA) 
forms of human plasma PLTP. 
2. To develop an enzyme-linked immunosorbent assay (ELISA) to quantita-
tively determine the HA- and LA-PLTP concentrations in human plasma. 
3. To study the distribution of the HA- and LA-PLTP and their relationship 
with lipid and carbohydrate parameters in a population sample. 
4. To investigate the regulation mechanisms of PLTP activation by studying 
the interactions of PLTP with apoA-I, apoE, and apoA-IV.  
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 4 MATERIALS AND METHODS 
4.1 List of published methods 
The methods used in the original articles and in this thesis are listed in the table 
below in alphabetical order. The Roman numerals indicate the original publication, 
in which the corresponding method is described. 
Method Original publication 
Activation experiments of LA-PLTP IV 
Baculovirus expression of PLTP II, IV 
Biosensor analysis of PLTP interactions IV 
Detergent treatment of PLTP II 
Dextran-sulfate-CaCl2 precipitation of LA-PLTP II 
Enhanced Chemiluminescence detection I, II, IV 
Enzymatic lipid analysis I, III 
Genotyping of apoE III 
Heparin-Sepharose Affinity Chromatography I, II 
Hydrophobic Chromatography I 
Hydroxylapatite Chromatography I 
Immunoaffinity Chromatography I, II 
Immunoprecipitation of PLTP I 
Lowry protein determination I, II, III, IV 
Non-denaturing gradient gel electrophoresis IV 
Plasma apolipoprotein and lipoprotein analysis I, III, IV 
Plasma CRP, glucose, and insulin analysis III 
PLTP activity assay I, II, III, IV 
PLTP mass determination by an ELISA I, II, III, IV 
Preparation of antibodies I, II 
Preparation of apolipoproteins IV 
Preparation of proteoliposomes and reconstituted HDL IV 
Purification of HA- and LA-PLTP I, II, IV 
SDS-PAGE and Western blotting I, II, IV 
Size-exclusion chromatography I, II, IV 
Statistical analyses II, III 
55 
 5 RESULTS AND DISCUSSION 
5.1 The high-activity form of human plasma PLTP interacts with 
apoE and the low-activity form with apoA-I in vitro 
Human plasma contains two forms of PLTP. One form has been demonstrated to 
display high specific activity (high-activity form, HA-PLTP), while the other form 
has been found to display no detectable PL transfer activity (low-activity form, LA-
PLTP). Furthermore, these two PLTP forms in native human plasma have been 
shown to associate with distinct lipoprotein populations. In size-exclusion chroma-
tography, active PLTP has been demonstrated to elute in the position of HDL with 
an average mass of 160 kDa, whereas the LA-PLTP has been shown to elute be-
tween LDL and large HDL, corresponding to an average molecular size of 520 kDa 
(Oka et al., 2000a). As previous reports have only described the purification of ac-
tive PLTP (Barter et al., 1988; Jauhiainen et al., 1993; Pussinen et al., 1995; Tollef-
son et al., 1988) it was important to develop a method for the purification of the LA-
PLTP as well. 
5.1.1 Isolation and partial purification of the HA- and LA-PLTP               
H e p a r i n - S e p h a r o s e A f f i n i t y  C h r o m a t o g r a p h y  
PLTP has been suggested to contain a heparin binding domain (Day et al., 1994). In 
this thesis, we separated the two forms of PLTP by Heparin-Sepharose (H-S) affin-
ity chromatography. When fresh human plasma was subjected to a large-scale H-S 
column and recycled on the column overnight, 93 ± 5% (n=3) of the PLTP activity 
and 70 ± 15% (n=3) of the PLTP mass applied were bound to the matrix. The bound 
PLTP activity and mass were eluted with a linear 0-0.5 M NaCl gradient. The LA-
PLTP displayed lower affinity for heparin and eluted first at a NaCl concentration of 
0.15-0.2 M, while the HA-PLTP eluted at a 0.3-0.4 M concentration of NaCl (I, Fig. 
1). In this first step of purification, the total recoveries of PLTP activity and mass 
were 110 ± 16% (n=3) and 90 ± 21% (n=3), respectively. HA-PLTP fractions repre-
sented less than 5% of the total PLTP mass recovered. The specific activity of re-
covered HA-PLTP was 3.5 μmol/h/μg, and that of the LA-PLTP 0.04 μmol/h/μg. 
For a comparison, the specific activity of PLTP in whole human plasma was 0.36 ± 
0.22 μmol/h/μg as measured by the ELISA (Huuskonen et al., 2000a). The higher 
56 
 affinity of the HA-PLTP for heparin could be due to the contribution of other pro-
teins present in the protein complex, such as apoE. Alternatively, conformational 
differences between the LA- and HA-PLTP could also cause the difference in hepa-
rin binding affinity. 
To verify that the sizes of the isolated PLTP forms correspond to those present in 
human plasma, the two PLTP fractions were applied to size-exclusion chromatogra-
phy (I, Fig. 2). Both the LA- and HA-PLTP eluted in positions similar to those de-
scribed by Oka and coworkers (2000a). The LA-PLTP eluted in a position corre-
sponding to an average molecular mass of 520 kDa, while the HA-PLTP eluted with 
an average molecular mass of 160 kDa, demonstrating that H-S affinity chromatog-
raphy does not disturb the integrity of the native macromolecular complexes of the 
LA- and HA-PLTP. 
To further enrich the HA-PLTP isolated by a large-scale H-S affinity chromatogra-
phy column, the fractions containing PLTP activity were subjected to a small-scale 
H-S column (I, Fig. 7). The HA-PLTP retained by the column was eluted with a 
linear 0.1-1.0 M NaCl gradient. After the second step of purification, 73% of the 
PLTP activity applied to the column was recovered. Analysis of the eluted fractions 
revealed that apoA-I eluted immediately before PLTP, whereas apoE was found to 
co-elute with the HA-PLTP. The eluted fractions containing the HA-PLTP were 
subjected to a size-exclusion chromatography column to analyze the size of the HA-
PLTP complex (I, Fig. 4). The results indicated an elution position for the HA-PLTP 
corresponding to a molecular mass of 160 kDa. 
H y d r o x y l a p a t i t e  C h r o m a t o g r a p h y  
In the final step of the HA-PLTP purification, the fractions enriched with PLTP 
activity were combined and subjected to a hydroxylapatite [Ca5(PO4)3(OH)] chro-
matography column, which binds proteins through Ca2+ and OH- ions (I, Fig. 8).  
The bound material was eluted with a linear 1-50 mM sodium phosphate gradient 
followed by 100 mM sodium phosphate. PLTP activity eluted at a sodium phosphate 
concentration of approximately 20 mM. Of the HA-PLTP applied, the eluted frac-
tions contained 91% of PLTP mass, 36% of PLTP activity, and some apoE but no 
apoA-I. The majority of bound apoE and apoA-I was eluted with 100 mM sodium 
phosphate. Size-exclusion chromatography demonstrated that after the final step of 
the HA-PLTP purification, both PLTP activity and mass as well as apoE co-eluted in 
the position of 160 kDa corresponding to the elution position of the HA-PLTP of 
human plasma (I, Fig. 9). Thus, the methods used for the purification of the HA-
PLTP did not dissociate the molecular complex in which the HA-PLTP resides. In 
each purification step, the elution position of the HA-PLTP in size-exclusion chro-
matography remained unchanged in the presence or absence of high concentration (8 
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 M) of urea indicating that the HA-PLTP complex might represent i) a PLTP dimer, 
ii) a urea-resistant protein complex, or iii) a PLTP molecule associated with lipids. 
H y d r o p h o b i c  C h r o m a t o g r a p h y  
To further enrich the LA-PLTP isolated by a large-scale H-S affinity chromatogra-
phy, the fractions containing the majority of PLTP mass and only very little activity 
were subjected to hydrophobic chromatography on a butyl-Sepharose column (I, 
Fig. 3). The column was eluted with 50% ethanol, and 79% of the LA-PLTP mass 
could be recovered. The elution position of the LA-PLTP coincided with that of 
apoA-I, which comprised more than 90% of the total protein amount eluted. To 
analyze the size of the LA-PLTP complex after this purification step, the eluted 
fractions were applied to a size-exclusion chromatography column (I, Fig. 4). The 
LA-PLTP was found to elute with an approximated molecular mass of 520 kDa 
corresponding to the size of the LA-PLTP complex isolated from human plasma. 
However, when gel filtration analysis was performed in the presence of 8 M urea, 
the LA-PLTP was found to elute in a position corresponding to a molecular mass of 
160 kDa, indicating that high concentration of urea can partly dissociate the LA-
PLTP complex (I, Fig. 4). In principle, the LA-PLTP complex could represent a 
homomultimer of PLTP or PLTP associated with other plasma proteins and lipids. 
I m m u n o a f f i n i t y  C h r o m a t o g r a p h y  
The last step in the purification of the LA-PLTP comprised of an anti-PLTP immu-
noaffinity chromatography column prepared from the monoclonal antibody (mAb) 
against human PLTP (I, Fig. 5). Of the PLTP mass recovered from the hydrophobic 
chromatography column, 85% was retained by the anti-PLTP column and could be 
eluted by 0.1 M glycine, pH 2.5, containing 0.2% Tween 20. Most of the apoA-I did 
not bind to the matrix although a significant amount of apoA-I could be co-eluted 
with the LA-PLTP. Size-exclusion chromatography of the eluted LA-PLTP fractions 
revealed that the size of the LA-PLTP complex changed significantly in this purifi-
cation step (I, Fig. 4). The molecular mass of the LA-PLTP was found to be 160 
kDa corresponding to that of the HA-PLTP. However, no phospholipid transfer 
activity could be detected in the eluted LA-PLTP fractions. Binding of PLTP to its 
antibody might have dissociated a PLTP-apoA-I subcomplex, which may have origi-
nally been associated with large, HDL-like structures. High concentration of urea did 
not have any further influence on the size of the LA-PLTP complex (I, Fig. 4). 
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 5.1.2 Characterization of the partially purified HA- and LA-PLTP 
S D S - P A G E  a n a l y s i s  
Analysis of the HA-PLTP fraction after the last purification step by sodium dodecyl-
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Coomassie staining, and 
Western blotting revealed a strong protein band in the region of 110-120 kDa and a 
band of 80 kDa, which was identified as PLTP by Western blotting (I, Fig. 6A). In 
addition, three groups of bands in the regions of 65-75 kDa, 55-65 kDa, and 30-35 
kDa could be detected. Of these, the protein with a molecular mass of 34 kDa was 
identified as apoE by Western blotting. The identity and possible association of the 
other observed proteins with PLTP remains to be resolved. In the characterized HA-
PLTP fraction no apoA-I could be detected. 
Similar analysis of the LA-PLTP fraction after the last purification step revealed 
several protein bands with the apparent molecular masses of 80 kDa, 48 kDa, 40 
kDa, and 28 kDa (I, Fig. 6B). Of these, the protein with a molecular mass of 80 kDa 
was identified as PLTP and the protein with a molecular mass of 28.1 kDa as apoA-I 
by Western blotting. No apoE could be detected in the LA-PLTP fraction. 
I m m u n o p r e c i p i t a t i o n  o f  P L T P  
Previous in vitro and in vivo studies have suggested that PLTP is capable of binding 
to apolipoproteins (Barlage et al., 2001; Pussinen et al., 1998). Immunoprecipitation 
of human plasma as well as the LA- and HA-PLTP fractions obtained by size-
exclusion chromatography was performed to investigate the association of PLTP 
with apoA-I, the major apolipoprotein of HDL (I, Fig. 10). About 95% of the PLTP 
mass was removed by anti-PLTP polyclonal antibody (pAb) from plasma as well as 
from both the LA- and HA-PLTP fractions. Similarly, the anti-PLTP pAb efficiently 
removed most of the PLTP activity from plasma and the HA-PLTP fraction. The 
LA-PLTP was omitted in this analysis due to its non-detectable PL transfer activity. 
Immunoprecipitations were also performed using a pAb against apoA-I. This anti-
body precipitated about 80% of plasma PLTP protein, whereas only a minor 5% 
decrease was detected in plasma PLTP activity. Immunoprecipitation of the LA- and 
HA-PLTP fractions caused coprecipitation of 90% and 70% of the PLTP protein, 
respectively. However, only a marginal 3% decrease in the PLTP activity of the HA-
PLTP fraction could be observed. Similar results were obtained when the LA-PLTP 
fraction obtained from immunoaffinity chromatography and the HA-PLTP fraction 
obtained from hydroxylapatite chromatography were immunoprecipitated with the 
same antibodies against PLTP and apoA-I. 
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 These results indicate that the LA-PLTP and apoA-I form a physical complex, 
whereas the HA-PLTP does not form a tight complex with apoA-I. However, we 
observed that the HA-PLTP copurified with apoE, which is in agreement with the 
finding that during an inflammatory state PLTP activity increases significantly, and 
under these conditions the PLTP protein comigrates with apoE in two-dimensional 
gel electrophoresis (Barlage et al., 2001). In addition, active PLTP secreted from 
HepG2 cells has been shown to resemble the HA-PLTP in human plasma and coe-
lute with apoE in size-exclusion chromatography (Siggins et al., 2003). Recently, 
higher PLTP activity among type 2 diabetic patients has been demonstrated to be 
associated with increased apoE concentration (Tan et al., 2006). All these findings 
support the hypothesis that apoE may be involved in maintaining PLTP in its active 
form. Contrary to our findings, Cheung and Albers (2006) have reported that im-
munoprecipitation of human plasma with an anti-apoA-I antibody resulted in 98% 
coprecipitation of plasma PLTP activity, indicating that PLTP activity in human 
plasma associates with apoA-I containing lipoproteins. On the other hand, it has 
been reported that HDL isolated by ultracentrifugation contains up to 40% of the 
total plasma PLTP mass but only a minor portion of plasma PLTP activity (Oka et 
al., 2000a). Moreover, Huuskonen and coworkers (2000a) have shown that PLTP 
activity in human plasma correlates negatively with HDL cholesterol. The latter 
findings are in agreement with our observation that the LA-PLTP associated with 
apoA-I, the main apolipoprotein of HDL, is of low specific activity. 
5.2 The human plasma PLTP concentration is unevenly 
distributed between the high- and low-activity forms of PLTP 
Although the role of PLTP activity in different physiological conditions has been 
studied quite intensively, the significance of PLTP concentration is far from re-
solved. Besides the ELISA used to assay PLTP concentration in cell media and lys-
ates (Qu et al., 1999), three different methods to determine PLTP concentration in 
human plasma have been reported (Desrumaux et al., 1999a; Huuskonen et al., 
2000a; Oka et al., 2000b). However, the results of these reports are conflicting 
probably due to the presence of two forms of PLTP in human plasma (Oka et al., 
2000a) and different immunoreactivities of the antibodies used in mass assays 
against the two PLTP forms, as reported by Murdoch and colleagues (2002b). It has 
been suggested that PLTP adopts a different conformation when associated with 
lipoprotein particles of different size and surface curvature, which may result in 
either exposure or masking of epitopes on the surface of PLTP. Alternatively, inter-
action of PLTP with lipids and other proteins might lead to masking of epitopes and 
impaired immunoreactivity. The observation that PLTP mass and activity in human 
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 plasma do not correlate (Huuskonen et al., 2000a; Oka et al., 2000b) supports the 
finding of Murdoch and coworkers about differences in the reactivity of antibodies 
against the HA- and LA-PLTP. Only in one study a significant correlation between 
PLTP mass and activity has been reported (Desrumaux et al., 1999a). To resolve 
these discrepancies and to provide a tool for future analyses to study the physiologi-
cal implications of the distribution of PLTP between the two forms, we undertook to 
develop an ELISA method capable of determining the concentrations of both the 
HA- and LA-PLTP in human plasma.  
5.2.1 Effect of various detergents on the immunoreactivity of PLTP 
To investigate whether the HA- and LA-PLTP forms react differently against anti-
bodies, 40 ng of each PLTP form as determined by ELISA (Huuskonen et al., 
2000a) were subjected to SDS-PAGE under reducing conditions. Western blot 
analysis and semiquantitative scanning of the protein bands revealed that the inten-
sity of the HA-PLTP was approximately 3-fold stronger than the intensity of the 
LA-PLTP (II, Fig. 1A). This result indicated that, as compared to the LA-PLTP, the 
concentration of the HA-PLTP was underestimated by the ELISA due to weak im-
munoreactivity. Therefore, we decided to evaluate the impact of a sample pretreat-
ment with a denaturant on the immunoreactivity of PLTP in ELISA. 
The effects of five detergents including anionic sodium dodecyl sulphate (SDS), 
cationic cetyltrimethylammonium bromide (CTAB), zwitterionic CHAPS, nonionic 
n-octyl-β-D-glucopyranoside (OG), and nonionic polyoxyethylene sorbitan 
monolaurate (Tween 20) on the immunoreactivity of human plasma PLTP were 
investigated using the ELISA method (Huuskonen et al., 2000a). All detergents were 
assayed at 0.1%, 0.5%, and at the critical micellar concentration (CMC), which var-
ied from 0.007% for Tween 20 to 0.5% for CHAPS. Of the detergents tested, the 
anionic SDS was observed to cause the highest increase in the immunoreactivity of 
plasma PLTP at all assayed detergent concentrations (II, Table 1). Compared with 
plasma assayed without any detergent pretreatment, the immunoreactivity of PLTP 
increased 4-fold when plasma was treated with 0.5% SDS before the assay. No fur-
ther increase in immunoreactivity was obtained with higher concentrations of SDS. 
The other detergents caused only a modest increase (Tween 20), no increase at all 
(OG and CHAPS) or a decrease in PLTP immunoreactivity (CTAB). Hence, we 
decided to recalibrate the ELISA method by incorporating a sample pretreatment 
with 0.5% SDS, which most likely either disrupts interactions between PLTP and 
other proteins or lipids masking the antibody epitope or causes a conformational 
change leading to an exposure of the epitope. The other steps in the ELISA were 
performed as described by Huuskonen and coworkers (2000a). 
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 5.2.2 Calibration of the ELISA 
For the primary standardization, highly purified recombinant human PLTP (r-PLTP) 
produced in the baculovirus protein expression system (Huuskonen et al., 2000b) as 
well as active PLTP purified from human plasma were treated with 0.5% SDS for 30 
minutes at +22°C, and thereafter used to create standard curves in the range of 25-
100 ng PLTP/ml. The ELISA was found to be linear over the entire range used and 
suitable for the quantification of PLTP concentration as low as 12.5 μg/l (II, Fig. 2). 
The primary standard curves obtained either with r-PLTP or human plasma PLTP 
did not differ significantly from each other. Each primary standard point differed by 
an average of 4.3% from the mean value (n=3). 
To investigate the effect of serum components on the immunoreactivities of the HA- 
and LA-PLTP that were isolated as described (I), increasing amounts of each PLTP 
form was added to foetal bovine serum before the determination of their concentra-
tion with the ELISA. The mean recoveries of added HA- and LA-PLTP were 90% 
and 109%, respectively, indicating that serum does not interfere with the measure-
ment of either PLTP form. After exclusion of the possible interfering effect of serum 
on the ELISA, we established a secondary standard using a plasma sample from a 
healthy, normolipidemic male volunteer. When analyzed after SDS pretreatment, the 
mean PLTP mass in the secondary standard was 5.9 mg/l. The secondary standard 
was pretreated with 0.5% SDS and diluted to cover the PLTP mass range from 25 to 
200 ng PLTP/ml. The slope of the secondary standard curve was found to be similar 
to those obtained with the primary calibrators (II, Fig. 2 and Fig. 3). Each secondary 
standard value differed by an average of 8.3% from the mean value (n=8). The intra-
assay variation was 8% and the inter-assay variation 13%. 
5.2.3 Measurement of the PLTP concentrations in human serum 
T o t a l  P L T P  c o n c e n t r a t i o n  i n  s e r u m  
Total PLTP concentrations in human serum samples of 80 randomly selected indi-
viduals, representing a subsample of the Health 2000 Health Examination Survey 
(Aromaa & Koskinen, 2002), were determined by the recalibrated ELISA. In these 
subjects, the mean serum PLTP mass was 5.81 ± 1.33 mg/l (mean ± SD) covering 
the range of 2.78-10.06 mg/l, and the mean serum PLTP activity was 5.84 ± 1.39 
μmol/ml/h covering the range of 3.21-11.15 μmol/ml/h. This yields the mean spe-
cific activity of about 1.0 μmol/μg/h for total serum PLTP. A weak, yet significant 
correlation (r=0.345, p<0.01) between total serum PLTP mass and activity was ob-
served (II, Fig. 7A). In this study, the mean serum PLTP mass obtained is consid-
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 erably lower than reported previously with similar assays (Huuskonen et al., 2000a; 
Oka et al., 2000b) but close to that reported with a competitive immunoassay 
(Desrumaux et al., 1999a). The reason for these discrepancies is obviously the weak 
immunoreactivity of the active PLTP in its native conformation that was used as a 
primary calibrator in these assays (Huuskonen et al., 2000a; Oka et al., 2000b). This 
results in low absorbance values obtained with the active primary calibrator and, 
consequently, too high values are obtained for serum samples containing abundant 
LA-PLTP, whose epitopes are apparently fully exposed for the antibodies also in the 
native conformation of the protein.  
H A -  a n d  L A - P L T P  c o n c e n t r a t i o n s  i n  s e r u m  
To determine the proportions of the two PLTP forms in human plasma, separation of 
the HA- and LA-PLTP was necessary. For this purpose, we first applied size-
exclusion chromatography (II, Fig. 4.). When the fractions were analyzed for PLTP 
mass and activity without SDS pretreatment, almost all of the detectable PLTP mass 
eluted in the position of the LA-PLTP. However, when the mass assay was carried 
out with SDS pretreatment of the fractions, the distribution of PLTP mass between 
the LA- and HA-PLTP was evident. This is in agreement with the finding that anti-
bodies against PLTP display different reactivities to the HA- and LA-PLTP when 
they are in their native conformation (Murdoch et al., 2002b). The size-exclusion 
chromatography revealed that the LA-PLTP comprises about 65% of the total PLTP 
mass, whereas 35% of the total PLTP mass resides in the HA-PLTP fraction.  
To further investigate the proportions of the HA- and LA-PLTP in human plasma 
and reproducibility of the separation method, we performed repeated plasma runs on 
Heparin-Sepharose affinity chromatography (n=6) and determined PLTP mass both 
from the unbound and bound fractions (II, Fig. 5). The bound fractions were found 
to comprise about 40% of the total PLTP mass, and more than 95% of the PLTP 
activity applied bound to the column matrix, indicating that the bound fractions 
represented the HA-PLTP. The unbound fractions encompassed about 50% of the 
total PLTP mass with no detectable PLTP activity, thus representing the LA-PLTP 
form. The separated HA- and LA-PLTP, 40 ng of each protein form, were then sub-
jected to SDS-PAGE. Western blot analysis and scanning of the PLTP bands re-
vealed that the immunoreactivities of both the HA- and LA-PLTP were similar, 
suggesting that the partial denaturation of PLTP by SDS apparently increases the 
accessibility of epitopes on the HA-PLTP resulting in similar immunoreactivities of 
the two PLTP forms in the ELISA and more reliable values for PLTP concentrations 
(II, Fig. 1B). 
The mAb JH66, used as the capture antibody in the ELISA, was then used in immu-
noaffinity chromatography of human plasma to study the immunoreactivity of the 
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 mAb JH66 to the HA- and LA-PLTP forms (II, Fig. 6). We observed that of the 
PLTP activity applied, none was retained by the column and 35% of the total PLTP 
mass could be recovered from the unbound fractions as analyzed by the ELISA and 
denaturing SDS pretreatment of the samples. After elution of the column with 0.1 M 
glycine, pH 2.5, it was revealed that 67% of the total PLTP mass bound to the mAb 
JH66. In addition, if plasma was treated with 0.5% SDS and thereafter applied to the 
immunoaffinity chromatography column, all of the PLTP protein was retained by 
the column. These results further support the conclusion that after SDS pretreatment, 
the ELISA method is capable of measuring both PLTP forms of human plasma.  
D e v e l o p m e n t  o f  t h e  E L I S A  f o r  c l i n i c a l  u s e  
Although the two forms of PLTP can be separated by size-exclusion, Heparin-
Sepharose, and immunoaffinity chromatography methods, they are too cumbersome 
to be used in the analysis of a large number of serum samples. To overcome this 
problem, we decided to use dextran sulfate (DxSO4)-CaCl2 precipitation, which has 
been used in the purification of PLTP (Tu et al., 1993). We observed that after 
DxSO4-CaCl2 precipitation of human plasma, almost all of the PLTP activity could 
be recovered from the supernatant, while only trace amounts of PLTP protein could 
be measured unless the sample was pretreated with 0.5% SDS. This suggested that 
most of the LA-PLTP was precipitated, which was also confirmed by Western blot-
ting. Similarly, only negligible PLTP mass was detected for the HA-PLTP fraction 
separated by the three different chromatographic methods if the mass determination 
was performed without a denaturing sample pretreatment.  
To evaluate whether DxSO4-CaCl2 precipitation could be used to separate the HA- 
and LA-PLTP in plasma samples, we performed the analysis of PLTP activity and 
mass from precipitated normolipidemic plasma samples (n=8). By subtracting the 
HA-PLTP mass measured in the supernatant of the precipitated plasma sample from 
the total plasma PLTP mass, a good estimate of the LA-PLTP mass was obtained. 
The analysis revealed that on average 84% of the PLTP activity and 37% of the 
PLTP mass could be recovered in the supernatant, suggesting that 63% of PLTP 
mass, representing the LA-PLTP, had been precipitated. The distribution of PLTP 
mass obtained with DxSO4-CaCl2 precipitation was found to be similar to those 
obtained with the three different chromatographic methods, indicating that the HA-
PLTP represents approximately 40% and the LA-PLTP 60% of the total PLTP mass. 
Thus, DxSO4-CaCl2 precipitation is a preferable method for separation of the two 
PLTP forms especially when assaying a large number of samples. 
Having established the assay method suitable also for clinical use, we analyzed the 
mass of the HA- and LA-PLTP from the serum of 80 randomly selected Finnish 
subjects, representing a subsample of the Health 2000 Health Examination Survey 
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 (Aromaa & Koskinen, 2002). In this population, the total PLTP concentration was 
5.81 ± 1.33 mg/l (mean ± SD) and the mean HA-PLTP concentration 1.87 ± 0.85 
mg/l (mean ± SD), leading to an estimate LA-PLTP concentration of 3.94 ± 1.40 
mg/l in the precipitate. Thus, the HA-PLTP was found to represent 32% and the LA-
PLTP 68% of the total serum PLTP mass. The mean PLTP activity recovered in the 
supernatant represented 88% of the activity measured in serum before precipitation. 
This yields a specific activity of 2.7 μmol/μg/h for the HA-PLTP, which was found 
to be similar to that of active PLTP secreted by human hepatoma cells (Siggins et 
al., 2003). For a comparison, if our method had resulted in complete separation of 
the two PLTP forms, the specific activity of the HA-PLTP would have been 3.1 
μmol/μg/h demonstrating that DxSO4-CaCl2 precipitation, as a separation method, is 
close to optimal. Moreover, the HA-PLTP concentration displayed a stronger posi-
tive correlation with serum PLTP activity (r=0.536, p<0.01) than did total PLTP 
mass in serum (r=0.345, p<0.01), further demonstrating successful separation of the 
HA-PLTP from the LA-PLTP. No correlation between the LA-PLTP mass and se-
rum PLTP activity could be observed, which also illustrates the specificity of 
DxSO4-CaCl2 precipitation in the isolation of the two PLTP forms (II, Fig. 7). 
5.3 The high- and low-activity forms of PLTP correlate differently 
with lipid and carbohydrate parameters in a Finnish 
population sample 
The development of the ELISA method for quantitation of both PLTP forms in hu-
man plasma provides an accurate and useful tool for establishing the relationship of 
the HA- and LA-PLTP with associated lipoproteins and other plasma factors, as well 
as for detecting possible changes in the distribution of human PLTP concentration in 
clinical serum samples originating from different physiological conditions. In this 
thesis, the influence of plasma lipoprotein profile and lipid composition, as well as 
some parameters of glucose metabolism, on the balance between the LA- and HA-
PLTP populations in Finnish individuals participating in the Health 2000 Health 
Examination Survey was investigated. The study was approved by The Working 
Group for Cardiovascular Diseases and Diabetes and by The Planning and Steering 
Group of the Research for the Health 2000 Health Examination Survey. 
5.3.1 Characteristics of the study population 
For this study, 125 men and 125 women were randomly chosen as a subsample of 
the Health 2000 Health Examination Survey carried out in Finland (Aromaa & 
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 Koskinen, 2002). The mean age of the study population was 55 years, and the body 
mass index (BMI) 26.1 ± 4.0 (mean ± SD). A significant gender difference was 
observed in total cholesterol (TC), HDL cholesterol (HDL-C), and apoA-I, which 
were higher among women, whereas the waist-to-hip circumference ratio (WHR) 
and glucose were higher among men (III, Table 1). The other parameters studied did 
not differ significantly between genders. 
5.3.2 Measurement of the PLTP activities and concentrations in serum 
The analysis of PLTP activity was performed by two different radiometric methods. 
The exogenous assay (PLTPexo) measures PL transfer to exogenously added HDL 
(Damen et al., 1982), while the endogenous assay (PLTPendo) measures PL transfer 
to endogenous serum HDL (Lagrost et al., 1999a). We observed that the two assays 
resulted in quite different values for serum PLTP activity. The mean serum PLTPexo 
activity was 6.59 ± 1.66 μmol/ml/h (mean ± SD), whereas the serum PLTPendo activ-
ity was 1.37 ± 0.29 μmol/ml/h (III, Table 2). No significant difference between gen-
ders was observed in the PLTP activity. 
The serum HA- and LA-PLTP concentrations were quantitated by the ELISA 
method as described (II). The mean total PLTP concentration in sera of 250 subjects 
was 6.56 ± 1.45 mg/l, covering the range of 2.78-10.89 mg/l. Similar values for 
PLTP concentration have been reported earlier with a competitive ELISA 
(Desrumaux et al., 1999a). The mean HA-PLTP concentration was 3.00 ± 1.21 mg/l 
and the mean LA-PLTP concentration 3.56 ± 1.14 mg/l. However, a large individual 
variation existed between the relative amounts of the two PLTP forms as the con-
centration ranges were 0.92-7.63 mg/l for the HA-PLTP and 1.20-8.43 mg/l for the 
LA-PLTP (III, Table 2). Like serum PLTP activity, PLTP concentrations did not 
differ significantly between genders.  
Serum PLTPexo activity showed a significant positive correlation with total serum 
PLTP concentration (r=0.45, p<0.001) and HA-PLTP concentration (r=0.38, 
p<0.001). Furthermore, a weak positive correlation (r=0.17, p<0.01) was observed 
between PLTPexo activity and LA-PLTP concentration (III, Fig. 1), whereas serum 
PLTPendo activity demonstrated a weak positive correlation only with HA-PLTP 
concentration (III, Table 3). A significant negative correlation between serum HA- 
and LA-PLTP was detected (III, Fig.2). 
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 5.3.3 Correlation of PLTP with clinical and biochemical parameters 
To investigate how the two PLTP forms relate to lipid and carbohydrate metabolism 
and to find possible regulatory factors for the two PLTP forms, we performed a 
statistical analysis between the PLTP parameters and selected clinical as well as 
biochemical parameters (III, Table 4). Total serum PLTP concentration correlated 
positively with age, and PLTPexo activity with BMI and WHR, which is in accor-
dance with previous findings (Huuskonen et al., 2000a; Jonkers et al., 2003). In 
addition, PLTPendo activity showed a negative correlation with age. We observed that 
none of the PLTP parameters correlated with gender or CRP in the studied population 
sample, which was composed of normolipidemic individuals. It has been reported, 
however, that in patients with a severe acute phase response, PLTP activity correlates 
positively and PLTP mass negatively with CRP. Furthermore, in these patients, PLTP 
mass was found to correlate negatively with SAA (Pussinen et al., 2001b). 
In this study sample, total serum PLTP concentration and HA-PLTP concentration 
were found to display a similar positive correlation with HDL-C. In addition, HA-
PLTP mass correlated positively with apoA-I. Similar relationship between PLTP 
mass and HDL-C has also been reported earlier (Oka et al., 2000b; Oka et al., 2002). 
A weak negative correlation was observed between total PLTP mass and TG, while 
no measured lipid parameter correlated with LA-PLTP concentration. Serum 
PLTPendo activity demonstrated a significant positive correlation with all studied 
lipid and lipoprotein parameters but apoB. By definition, the assay is dependent on 
the serum HDL-C and will therefore correlate with the HDL-C and apoA-I (Lagrost 
et al., 1999a). The correlation of PLTPendo activity also with TC, TG, and LDL cho-
lesterol (LDL-C) suggests that other lipoproteins affect the outcome of the assay as 
well. Furthermore, PLTPendo activity showed a weak positive correlation only with 
HA-PLTP mass, suggesting that the assay rather reflects the activity of PLTP as 
modulated by the composition and concentration of endogenous lipoproteins than 
the amount of active PLTP in serum. As PLTPexo activity showed a positive correla-
tion with total, HA- and LA-PLTP concentrations, it is a preferable method for de-
termining the serum PLTP activity levels. In addition, positive correlations between 
PLTPexo activity and serum TC, TG, apoB, and apoE were observed. However, 
unlike previous reports (Cheung et al., 2002; Murdoch et al., 2000), no correlation 
between PLTPexo activity and LDL-C was found in this study population. This indi-
cates that PLTP activity might correlate with VLDL, which is in agreement with the 
hypothesis of Murdoch and colleagues (2002a) who suggested that the increase of 
apoB associated with VLDL particles results in increased PLTP activity to facilitate 
the transfer of post-lipolytic PL-rich surface remnants to HDL.  
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 As a weak positive correlation between PLTPexo activity and apoE was observed, 
and it has been shown that serum apoE concentration is dependent on the apoE 
genotype (Smit et al., 1988), apoE allele distribution in the study population was 
analyzed. ApoE allele frequencies in the study sample were observed to be similar to 
those reported earlier for Finns (Ehnholm et al., 1986). ApoE genotypes were di-
vided in three subgroups. Group 1 included the genotypes E3/E3 (n=137), group 2 
the genotypes E3/E4 and E4/E4 (n=78), and group 3 the genotypes E2/E2, E2/E3, and 
E2/E4 (n=17). The carriers of ε2 allele in group 3 showed significantly increased 
apoE concentration (p<0.001), TG concentration (p<0.05) as well as PLTPendo activ-
ity (p<0.001) as presented in Table 2. However, we did not detect any differences in 
PLTPexo activity or PLTP concentrations between the groups. Therefore, we con-
sider that the increased PLTPendo activity in group 3 is attributable to a difference in 
serum lipoprotein profile that is reflected in the outcome of the assay. 
In previous studies, PLTP concentration (Desrumaux et al., 1999a) and activity 
(Riemens et al., 1998b) have been associated with glucose metabolism. Therefore, 
the relationship of PLTP parameters with glucose and insulin was investigated. In 
addition, the homeostasis model assessment for insulin resistance (HOMA IR) cal-
culated from the fasting plasma glucose and serum insulin concentrations (Matthews 
et al., 1985) was used to investigate how the PLTP parameters relate with insulin 
resistance. Serum total and HA-PLTP concentrations as well as PLTPexo activity 
demonstrated a similar positive correlation with serum glucose concentration, 
whereas the LA-PLTP concentration tended to associate with serum insulin. Fur-
thermore, in this population sample, PLTPexo activity was observed to correlate posi-
tively with insulin resistance determined as HOMA IR, which is in agreement with 
previous findings (Jonkers et al., 2003; Riemens et al., 1998b). 
The present study suggests that both lipid and glucose metabolism affect the distri-
bution of the two PLTP forms and the level of PLTP activity in serum. The finding 
Table 2. Characteristics of the subgroups of apoE isoforms (mean ± SD) 
 
ApoE (mg/l) TG (mmol/l) PLTPendo activity (μmol/ml/h) 
Group 1 (n=137) 28.1 ± 14.5 1.45 ± 0.84 1.35 ± 0.18 
Group 2 (n=78) 20.7 ± 15.8 1.42 ± 0.87 1.35 ± 0.19 
Group 3 (n=17) 39.9 ± 18.6a 2.12 ± 2.55b 1.64 ± 0.88a
ap<0.001, bp<0.05 
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 that the expression of the PLTP gene is regulated by glucose via a PPAR-mediated 
pathway further supports the relationship between PLTP and glucose metabolism 
(Tu & Albers, 2001) although the detailed mechanisms by which glucose and insulin 
could modulate the distribution of the HA- and LA-PLTP remain to be resolved. 
5.4 ApoE and apoA-IV activate the low-activity form of human 
PLTP 
Exchangeable apolipoproteins play an essential role in HDL assembly and metabo-
lism. Numerous apolipoproteins have been found to function as co-factors for differ-
ent plasma enzymes and lipid transfer proteins regulating HDL metabolism and to 
enhance their activities. The factors regulating PLTP activity as well as the distribu-
tion of PLTP between the two forms are currently unknown and may involve inter-
actions of PLTP with apolipoproteins. PLTP has been reported to interact both with 
apoA-I and apoA-II (Pussinen et al., 1998). In addition, we observed that the HA-
PLTP copurifies with apoE, while the LA-PLTP is associated with apoA-I (I), and 
that PLTP activity correlates positively with apoE (III). Therefore, interactions of 
the two PLTP forms with apolipoproteins as well as the ability of apolipoproteins to 
transform the low-activity form of PLTP into an active form were investigated. 
5.4.1 Interactions of apolipoproteins with PLTP 
In this thesis, the binding of recombinant PLTP (r-PLTP), representing an active 
PLTP form, and the low-activity form of human plasma PLTP (LA-PLTP) to apoA-
I, apoA-IV, and apoE using surface plasmon resonance analysis on a Biacore 2000 
instrument was investigated in more detail. To minimize the effects of contaminat-
ing serum proteins on the interactions, r-PLTP was primarily chosen to be used as an 
analyte and recombinant apoE and apoA-IV, or highly purified apoA-I were used as 
immobilized ligands on the sensor chip surface. The sensorgrams obtained with the 
Biacore instrument clearly demonstrated a concentration-dependent binding of both 
analytes, r-PLTP and LA-PLTP, to apoA-I and apoE within a nanomolar range (IV, 
Fig. 1). Both analytes also showed binding to apoA-IV. A polyclonal anti-PLTP 
antibody was used as an additional analyte after injection of PLTP to demonstrate 
that a stable association of PLTP with apolipoproteins and not only a donation of 
phospholipids was taking place on the sensor chip surface. The relatively low Rmax 
values, presented as resonance units (RU), indicate that the interactions were fast 
and varied in their stability. Regarding the binding of PLTP, this may in part be due 
to unfavorable orientations of the apolipoproteins on the surface of a flow cell. The 
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 effect of each PLTP concentration on the binding response at a steady-state phase of 
each interaction was evaluated. These equilibrium-binding responses (IV, Fig. 2) 
demonstrate that in the interactions where the saturation level was reached, the esti-
mated KD values were comparable with the KD values derived from the reaction 
rates obtained from the sensorgram data (IV, Table 2).  
The binding affinities of r-PLTP and LA-PLTP to apoA-I, apoA-IV, and apoE were 
determined from rate equations by simultaneous ka/kd simulated kinetics using a 
Langmuir model (IV, Table 2). Several other models, including a two-state reaction, 
bivalent analyte, and parallel reactions, supported the KD values obtained by using 
the Langmuir model. Data obtained using the different kinetic models suggest that 
the interactions of PLTP with apolipoproteins involve more complex binding dy-
namics, which is possibly influenced by phospholipids associated with PLTP, than a 
simple 1:1 -binding stoichiometry. We observed that both PLTP forms had different 
affinities for the three apoE isoforms, apoE2, apoE3, and apoE4. Due to the slow 
dissociation rates (kd) of the analytes, apoE2 was found to be the most stable binding 
partner, whereas binding of both r-PLTP and LA-PLTP to the other apolipoproteins 
was driven by fast association kinetics. The binding affinities and interaction rates of 
r-PLTP with the apoE isoforms were similar to those of LA-PLTP. However, the 
association rate (ka) of active r-PLTP with apoA-I was 10-fold slower than that of 
LA-PLTP. Due to the fast dissociation rate of LA-PLTP from apoA-I, the corre-
sponding KD value for this interaction remained relatively high. In contrast to apoA-
I, the affinity of apoA-IV was lower for r-PLTP than for LA-PLTP. This was ob-
served to be due to the fast dissociation rate of r-PLTP from apoA-IV. The mean χ2 
values, 2.65 for r-PLTP and 0.50 for LA-PLTP, illustrate the reliability of the re-
sults. Thus, both the active r-PLTP and the LA-PLTP interact with apoA-I, apoA-
IV, and apoE, albeit with different affinities and interaction rates. The physiological 
importance of the different affinities of PLTP for the apoE isoforms remains a topic 
for future studies. 
5.4.2 Activation of the LA-PLTP with apoE and apoA-IV 
To examine the possible physiological roles of apolipoproteins in the regulation of 
PLTP activity, proteoliposomes containing apoA-I, apoA-IV, or apoE as protein 
constituent, as well as phosphatidylcholine and unesterified cholesterol, were pre-
pared by the cholate dialysis technique (IV, Table 1). The incubations of proteolipo-
somes with the LA-PLTP, which had no detectable PL transfer activity, were carried 
out at +37°C for 30 minutes, after which the preincubated samples were assayed for 
PLTP activity. The incubation of the apoE proteoliposomes with the LA-PLTP at 
different molar ratios resulted in a concentration-dependent activation of the LA-
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 PLTP (IV, Fig. 3). The mean PLTP activity of 264 nmol/ml/h was reached after the 
incubation with the highest concentration of apoE proteoliposomes. No differences 
between the proteoliposomes containing apoE2, apoE3, or apoE4 in their ability to 
activate the LA-PLTP were observed. This is in line with the observation that in a 
Finnish population sample apoE genotype had no influence on the PLTP activity 
(III). The proteoliposomes containing apoA-IV were also capable of activating the 
LA-PLTP to a similar extent as the apoE proteoliposomes. No significant differ-
ences in LA-PLTP activation were detected whether native HDL3 or reconstituted 
HDL particles were used as acceptors in the PLTP-activity assays. However, no 
activation of the LA-PLTP could be detected when incubations were performed with 
proteoliposomes containing apoA-I, which supports the previous finding that apoA-I 
is a major component of the LA-PLTP complex (I). These results suggest that apoE 
and apoA-IV, and possibly some other apolipoproteins, play a role in the regulation 
of PLTP activity. In agreement with this, PLTP activity has been shown to correlate 
positively with apoE, and PLTP has been shown to colocalize exclusively with 
apoE-containing HDL particles in patients with a chronic inflammation (Barlage et 
al., 2001). Furthermore, it has been suggested that apoA-IV could act as an activator 
for the HDL conversion factor, which was later revealed to be PLTP. On the other 
hand, neither apoA-I, apoA-II, apoC, nor apoE could enhance the remodeling of 
HDL3 particles by the conversion factor (Barter et al., 1988). However, infusion of 
apoA-I/PL discs into human subjects has been shown to result in increased forma-
tion of preβ-HDL particles (Nanjee et al., 1999) and elevated PLTP activity with a 
concomitant decrease in PLTP concentration (Kujiraoka et al., 2004). Contrary to 
these findings, we could not observe any enhancement of PLTP-mediated phosphol-
ipid transfer by apoA-I, apoE, or apoA-IV, which were incubated with the HA-
PLTP (data not shown). Consistent with our finding that the LA-PLTP associates 
with apoA-I, the low plasma PLTP concentration in patients with hypoalphalipopro-
teinemia and the increased PLTP concentration in subjects with CETP deficiency 
have been demonstrated to be due to differences in the concentration of inactive 
PLTP, while the levels of active PLTP remained comparable to those of the control 
subjects. Moreover, the changes in PLTP concentrations were accompanied by al-
terations in the relative proportions of large HDL particles containing inactive PLTP 
and smaller particles containing active PLTP, suggesting that plasma lipoprotein 
profile regulates the abundance of the HA- and LA-PLTP forms (Oka et al., 2002). 
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 6 SUMMARY AND CONCLUSIONS 
The presence of two different forms of PLTP, associated with macromolecular com-
plexes of different size, has been demonstrated in human plasma (Oka et al., 2000a). 
In the first part of this thesis, a method to isolate these two PLTP forms from human 
plasma was developed and the molecular complexes in which the HA- and LA-
PLTP reside were partially characterized. It was observed that the HA-PLTP copuri-
fied with apoE, whereas the LA-PLTP formed a complex with apoA-I. 
The second part of this thesis aimed at developing an ELISA method that enables 
quantitation of the two PLTP forms in human plasma. Partial denaturation of PLTP 
by SDS was found to apparently increase the accessibility of epitopes on the surface 
of the HA-PLTP and to result in similar immunoreactivity of both PLTP forms. The 
separation of the two PLTP forms is necessary before their mass determination. For 
the analysis of a large number of serum samples, DxSO4-CaCl2 precipitation is a 
preferable approach to separate the HA- and LA-PLTP. The ELISA method devel-
oped for quantitation of both PLTP forms in human plasma provides an accurate 
tool for studing the relationship of the HA- and LA-PLTP with lipoproteins and 
other plasma factors, as well as for detecting possible changes in the distribution of 
human PLTP in different physiological conditions and disease states. 
In the third part of this thesis, the influence of serum parameters related to lipid and 
glucose metabolism on the balance between the LA- and HA-PLTP as well as the 
distribution of the two PLTP forms in a population sample were investigated. 
Among Finnish individuals participating in the Health 2000 Health Examination 
Survey, the mean PLTP mass was 6.6 ± 1.5 mg/l and the mean PLTPexo activity 6.6 
± 1.7 μmol/ml/h. Of the serum PLTP concentration, almost 50% represents HA-
PLTP. A large individual variation, however, was detected in the distribution of the 
two PLTP forms. Both total PLTP and HA-PLTP concentrations were found to cor-
relate positively with HDL-C. In addition, correlation of PLTP activity with TC, TG, 
apoB, and apoE suggests that PLTP activity could be regulated by plasma VLDL 
concentration. Of the studied parameters of glucose metabolism, glucose correlated 
positively with serum total PLTP and HA-PLTP concentration, whereas LA-PLTP 
concentration showed a positive correlation with serum insulin. Furthermore, PLTP 
activity was found to be related to insulin resistance. These results support the pre-
vious findings that in addition to lipoprotein metabolism, PLTP could also play a 
role in glucose metabolism. 
In this thesis, it was observed that the HA-PLTP of human plasma copurifies with 
apoE and serum PLTP activity correlates positively with apoE concentration. There-
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 fore, interaction of PLTP with apolipoproteins and the ability of apolipoproteins to 
regulate PLTP activity were studied. Using surface plasmon resonance analysis, we 
observed that both r-PLTP, representing an active PLTP form, and the LA-PLTP 
interact with apoA-I, apoA-IV, and apoE. In addition, apoE and apoA-IV, but not 
apoA-I, are capable of activating the LA-PLTP. These findings suggest that the dis-
tribution of the HA- and LA-PLTP in human plasma is subject to a dynamic regula-
tion by apolipoproteins. 
Based on the findings reported in this thesis, a model is suggested (Fig. 5) in which 
nascent PLTP of high specific activity enters the circulation possibly associated with 
the secreted nascent VLDL particles. After the transfer of post-lipolytic, PL-rich sur-
face remnants of TG-rich lipoproteins to HDL, a portion of PLTP may become associ-
ated with apoA-I in large HDL-like particles, and thereby be sequestered into the LA-
PLTP complex. Whether this is a reversible process also in vivo or whether the LA-
PLTP is just an intermediate directed to the catabolic route remains to be resolved. 
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Figure 5. A schematic model for the conversion of the HA-PLTP to the LA-PLTP. The 
boomerang-shaped PLTP molecule is secreted from the liver as a high-activity form 
probably associated with apoE on the surface of VLDL (1). During or after the transfer 
of lipolytic surface remnants of TG-rich lipoproteins to lipid-poor HDL (2), PLTP be-
comes associated with apoA-I in large HDL-like particles and loses measurable PL 
transfer activity (3). The thus formed LA-PLTP can be catabolized together with apoA-
I through the kidney (4) or taken up by the liver for degradation (5). Alternatively, 
changes in the plasma lipoprotein profile and in the associations with apolipoproteins 
can re-activate LA-PLTP (6).  
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